UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 10-K

(Mark One)
[ ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                   For the fiscal year ended December 31, 2007
                                       OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                 For the transition period from ______ to _____

                         Commission File Number 0-52263


                               CAVIT SCIENCES, INC

A Florida Corporation                                IRS Employer No. 03-0586935

                    20 NW 181st Street, Miami, Florida 33169
                          Telephone No. (305)-493-3304

        Securities registered pursuant to Section 12(b) of the Act: None

           Securities registered pursuant to Section 12(g) of the Act:

                                                           Name of Each Exchange
          Title of Each Class                               on Which Registered
          -------------------                               -------------------
Common Stock, $.01 par value per share                        Not applicable

Indicate by check mark if the  registrant  is a  well-known  seasoned  issuer as
defined in Rule 405 of the Securities Act. Yes [ ] No [X]

Indicate  by  check  mark if the  registrant  is not  required  to file  reports
pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X]

Indicate  by check  mark  whether  the  registrant:  (1) has filed  all  reports
required by Section 13 or 15(d) of the  Securities  Exchange  Act of 1934 during
the  preceding  12 months (or for such  shorter  period that he  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark if disclosure of delinquent  filers  pursuant to Item 405
of Regulation S- K is not contained  herein,  and will not be contained,  to the
best  of  the  registrant's   knowledge,  in  definitive  proxy  or  information
statements  incorporated  by  reference  in Part  III of this  Form  10-K or any
amendment to this Form 10-K. [ ]

Indicate by check mark whether the registrant is a large  accelerated  filer, an
accelerated filer, a non-accelerated  filer or a smaller reporting company.  See
definitions  of  "accelerated  filer,"  "large  accelerated  filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]                        Non-accelerated filer [ ]
Accelerated filer [ ]                              Smaller reporting company [X]

Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Act). Yes [ ] No [X]

The  aggregate  marker  value of  common  stock  held by  non-affiliates  of the
Registrant as of March 31, 2008, was approximately $2,796,187.

On March 31,  2008,  19,399,356  shares of the  Registrant's  common  stock were
outstanding.

                    DOCUMENTS INCORPORATED BY REFERENCE: None
<PAGE>
                                TABLE OF CONTENTS

                                                                            Page
                                                                            ----
PART I

Item 1.     Description of Business                                            1
Item 1A.    Risk Factors                                                       4
Item 2.     Description of Property                                           15
Item 3.     Legal Proceedings                                                 15
Item 4.     Submission of Matters to a Vote of Security Holders               15

PART II

Item 5.     Market For Common Equity and Related Stockholder Matters
             and Issuer Purchases of Equity Securities                        15
Item 6.     Selected Financial Data                                           19
Item 7.     Management's Discussion and Analysis of Financial Condition
             and Results of Operation                                         19
Item 8.     Financial Statements and Supplementary Data                       22
Item 9.     Changes in and Disagreements With Accountants on
             Accounting and Financial Disclosure                              22
Item 9A.    Controls and Procedures                                           22
Item 9B.    Other Information                                                 24

PART III

Item 10.    Directors, Executive Officers and Corporate Governance            24
Item 11.    Executive Compensation                                            27
Item 12.    Security Ownership of Certain Beneficial Owners and Management
             and Related Stockholder Matters                                  30
Item 13.    Certain Relationships and Related Transactions                    32
Item 14.    Principal Accountant Fees and Services                            32
Item 15.    Exhibits, Financial Statement Schedules                           33

                                       i
<PAGE>
                              CAUTIONARY STATEMENT

     This Form 10-K contains forward-looking statements. These statements relate
to future events or future  financial  performance and involve known and unknown
risks,  uncertainties  and  other  factors  that may cause  the  Company  or its
industry's actual results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity, performance or
achievements expressed or implied by the forward-looking statements.

     In some cases, you can identify  forward-looking  statements by terminology
such as "may," "will," "should," "expects," "plans," "anticipates,"  "believes,"
"estimates,"  "predicts,"  "potential,"  or the negative of these terms or other
comparable terminology. These statements are only predictions.  Actual events or
results  may  differ   materially.   Although  the  Company  believes  that  the
expectations  reflected in the  forward-looking  statements are reasonable,  the
Company cannot  guarantee  future  results,  levels of activity,  performance or
achievements.  The Company is under no duty to update any of the forward-looking
statements  after the date of this Form 10-K to confirm its prior  statements to
actual results.

     Further,  this Form 10-K contains  forward-looking  statements that involve
substantial  risks  and   uncertainties.   Such  statements   include,   without
limitation,  all statements as to expectation or belief and statements as to our
future results of operations,  the progress of any research, product development
and  clinical  programs,  the need for,  and timing of,  additional  capital and
capital expenditures,  partnering prospects,  the protection of and the need for
additional  intellectual property rights,  effects of regulations,  the need for
additional facilities and potential market  opportunities.  The Company's actual
results  may  vary  materially  from  those  contained  in such  forward-looking
statements  because of risks to which the  Company is  subject,  such as lack of
available funding, competition from third parties,  intellectual property rights
of third parties,  regulatory  constraints,  litigation and other risks to which
the Company is subject.

                                       ii
<PAGE>
                                     PART I

ITEM 1. BUSINESS.

OVERVIEW

     On April  12,  2006,  we were  incorporated  under the laws of the State of
Florida  and  became a  subsidiary  of Hard to Treat  Diseases,  Inc.  ("Hard to
Treat").  We chose the name Cavit Sciences,  Inc. based on "Cavit" as an acronym
for cancer and viral infection treatment.  Cavit Sciences, Inc. will be referred
to herein as "Cavit" and/or as "Company."

     We are a biotechnology  company engaged in developing  treatments of cancer
and viral infections.  Our strategy is to develop and commercialize intellectual
property rights to treat, prevent and inhibit several major diseases,  including
cancers,  viral  infections  and  diseases  associated  with  cancers  and viral
infections.

     We  currently  own  twelve  patent   applications  and  intend  to  acquire
additional ones. One of our  applications is a U.S.  utility patent  application
relating to  compositions  and methods for  inhibition of viral  infections  and
therapeutic  treatment of diseases or disorders caused by viral infections.  Our
second  application  is a  Patent  Cooperation  Treaty  or  PCT  utility  patent
application  relating  to  compositions  and  methods  for  inhibition  of viral
infections and  therapeutic  treatment of diseases or disorders  caused by viral
infections.  Our third  application  is a U.S.  provisional  patent  application
relating to  compositions  and methods for inhibition of cancers and therapeutic
treatment of diseases or disorders  caused by cancers.  Patent  Application  #'s
4-10 are the result of an additional PCT Utility  Application and National Phase
filings in various countries. Patent Application #'s 11 and 12 are the result of
adding  nineteen  additional  compounds  for various  treatments to our previous
applications through the filing of Continuation-In-Part applications.

     We acquired these intellectual  property rights from Hard to Treat Diseases
on May 31, 2006 in exchange for  8,475,000  shares of our common  stock.  During
2006,  we were  assigned  a portion of the patent  application  rights  entitled
"Methods and Compositions of Treatment of Viral Infections" for $30,000.

     Cancers and viral  infections  destroy the lives of millions of people each
year. Drug companies are spending millions of dollars on research and testing in
order to bring new drugs to market.  Current treatments are normally  expensive,
painful and do not always promote better health.

     In addition to the  treatment  of cancer and viral  infections,  our patent
applications  claim  the  treatment  of  numerous  additional  diseases.   These
substances  act to increase  the  strength of the immune  system by warding off,
inhibiting and treating diseases.

     In addition, Cavit acquired a food supplement line during February 2007. As
a result of  agreements  entered into with Daycon  Investors  Associates,  Inc.,
Americare  Nutritional  Division and Dr. Jospeh P. D'Angelo,  Cavit acquired the
foundation of two premium supplement lines which were developed during 2007. The
core products in Cavit's supplement lines will enhance and improve the prostate,

                                        1
<PAGE>
maintain  and  support  the  cardiovascular   system,  and  beneficially  effect
arthritis and  osteoporosis.  Superior results have been attained by individuals
with the use of Cavit's  products.  These proven results are due to the research
and testing of the most  effective  formulas  with  nutrients  that  support and
supplement each other at the optimum dosage of each ingredient. Cavit intends to
manufacture,  market, distribute and commercialize a range of supplements to act
as powerful antioxidants and immune enhancers which have beneficial effects upon
many serious diseases.

     Cavit's  current  facilities  accommodate  its  laboratories,  research and
development,  warehouse and corporate offices. The facilities provide ample room
for the development of the food supplement  lines. The plants  laboratories will
be used for ongoing  research and development of existing  products and products
being  developed with innovation as our trend.  The facilities also  accommodate
Cavit's plant equipment,  staff, and relocated corporate  headquarters and allow
for future expansion.

     The food  supplement  lines are an ideal  match  with our drug  development
process.  In addition to creating a full range biotech  company,  the supplement
line will create a steady  stream of cash flow to support the  commercialization
of our drugs.

HISTORY OF INTELLECTUAL PROPERTY RIGHTS

     During 2004,  Hard to Treat began to  internally  develop the  intellectual
property  rights  that were  acquired by Cavit on May 31,  2006,  as part of the
operations of Hard to Treat's biotechnology division.

     During 2004, Hard to Treat conducted the research and development  that was
the  foundation  for the  first  patent  application  filed  by Hard to Treat in
December  2004. As a result of  additional  research and  development  conducted
during 2005, Hard to Treat filed two additional patent  applications in December
2005. Cavit was  incorporated on April 12, 2006 and acquired these  intellectual
property rights from Hard to Treat on May 31, 2006. In July 2006, Cavit acquired
all other outstanding rights to these intellectual  property rights from a third
party.

     During 2007, Cavit filed an additional PCT Utility patent application,  six
National Phase applications, and two Continuation-In-Part  applications. Cavit's
intellectual property rights currently consist of twelve patent applications.

LICENSES, PATENTS AND PROPRIETARY RIGHTS

     We believe that proprietary protection of our technologies will be critical
to the  development  of our  business.  We intend  to  protect  our  proprietary
intellectual  property through patents and other appropriate means. We rely upon
trade  secret  protection  for certain  types of  confidential  and  proprietary
information and take active measures to control access to that  information.  We
currently  have  non-disclosure   agreements  with  all  of  our  employees  and
consultants.

                                        2
<PAGE>
RESEARCH COLLABORATIONS

     We anticipate entering into collaborative research agreements with academic
and research institutions.  We will use these agreements to enhance our research
capabilities.  In our industry,  these agreements typically provide the industry
partner with rights to license the  intellectual  property  created  through the
collaboration.  We may also enter into  collaborative  research  agreements with
other  pharmaceutical  companies  if necessary  to support the  development  and
commercialization of our technology.

COMMERCIALIZATION THROUGH THIRD PARTIES

     We may grant  sublicenses  for certain  applications  of our  technologies.
Sublicensing  certain rights in our technology to  pharmaceutical  companies and
other third  parties help us to  efficiently  develop some  applications  of our
technologies.

COMPETITION

     The  development of  therapeutic  cancer and viral  infection  products for
human disease is intensely competitive. Major pharmaceutical companies currently
offer a number of pharmaceutical products to treat cancers,  infectious diseases
and  other  diseases  for  which  our  technologies  may  be  applicable.   Many
pharmaceutical  and  biotechnology  companies  are  investigating  new drugs and
therapeutic  approaches  for the same  purposes,  which may achieve new efficacy
profiles,  extend the therapeutic window for these products, alter the prognosis
of these diseases or prevent their onset.  We believe our products,  when and if
successfully  developed,  will  compete  with  these  products  on the  basis of
improved and extended  efficacy and safety and their overall economic benefit to
the health care system.  We expect  intense  competition.  Our most  significant
competitors  will be fully integrated  pharmaceutical  companies and established
biotechnology companies.  Smaller companies may also be significant competitors,
particularly  through  collaborative  arrangements with large  pharmaceutical or
biotechnology  companies.  Many of our competitors have significant  products in
development that could compete with our potential  products.  The market for our
food supplement lines is also quite intense.  Practically all of our competitors
have more money and expertise than we have.

EFFECT OF EXISTING OR PROBABLE GOVERNMENTAL REGULATIONS

     The Company's  common stock is registered  pursuant to Section 12(g) of the
Securities  Exchange Act of 1934 ("1934 Act"). As a result of such registration,
the Company is subject to  Regulation  14A of the "1934  Act,"  which  regulates
proxy  solicitations.  Section  14(a)  requires all  companies  with  securities
registered  pursuant  to  Section  12(g)  thereof  to comply  with the rules and
regulations  of  the  Securities  and  Exchange   Commission   regarding   proxy
solicitations,  as outlined in Regulation 14A. Matters submitted to stockholders
of the Company at a special or annual  meeting  thereof or pursuant to a written
consent  will  require  the  Company  to  provide  its  stockholders   with  the
information  outlined in  Schedules  14A or 14C of  Regulation  14;  preliminary
copies of this  information must be submitted to the Commission at least 10 days
prior to the date that  definitive  copies of this  information are forwarded to
stockholders.

                                       3
<PAGE>
     The  Company  is also  required  to file  annual  reports  on Form 10-K and
quarterly reports on Form 10-Q with the Securities and Exchange  Commission on a
regular  basis,  and will be  required to  disclose  certain  events in a timely
manner (e.g.  changes in corporate  control;  acquisitions  or dispositions of a
significant amount of assets other than in the ordinary course of business) in a
Current Report on Form 8-K.

     Our research and development  activities and the future  manufacturing  and
marketing of our potential  products are, and will be, subject to regulation for
safety and efficacy by a number of governmental authorities in the United States
and other countries.

     In the United States,  pharmaceuticals,  biological and medical devices are
subject to Food and Drug Administration  regulation.  The Federal Food, Drug and
Cosmetic  Act, as amended,  and the Public Health  Service Act, as amended,  the
regulations  promulgated  thereunder,  and other Federal and state  statutes and
regulations  govern,  among other  things,  the  testing,  manufacture,  safety,
efficacy,  labeling,  storage,  export,  record  keeping,  approval,  marketing,
advertising  and promotion of our potential  products.  Product  development and
approval  within this  regulatory  framework take several  years,  cost a lot of
money and involve significant uncertainty.

     We are also subject to regulations under the Occupational Safety and Health
Act, the  Environmental  Protection  Act, the Toxic  Substances  Control Act and
other  present  and  potential   future  foreign,   Federal,   state  and  local
regulations.

EMPLOYEES

     As of April 10, 2008, we had two full time employees, Mr. Colm King, who is
our President and Chief Executive Officer, and Susan King, who is our Accountant
and  Administrator.  We believe that our relations  with our employees are good.
Our employees and spouse of Colm King, are not represented by a union or covered
by a  collective  bargaining  agreement.  We believe  Mr. King is best suited to
oversee the  operations  of Company  during the next  several  months due to his
intimate  knowledge  of our  biotechnology  business.  From  November 1, 2006 to
January 18, 2008,  Mr.  Julio De Leon served as the  Company's  Chief  Financial
Officer on an independent  contractor  basis. As of January 21, 2008 Mr. Matthew
J. Cohen became the Chief Financial Officer on an independent  contractor basis.
As of November 11,  2007,  Miles  Benzler  became the  Marketing  Director on an
independent  contractor  basis.  We will  actively  recruit and hire a new chief
operating  officer  and  additional   technical   employees  when  funds  become
available.  We intend to fill these posts with individuals having pharmaceutical
and/or biotechnology experience and expertise.

ITEM 1A. RISK FACTORS

     An  investment  in our  common  stock  involves  a  high  degree  of  risk.
Prospective  investors should carefully  consider the following risk factors and
the other  information  in this Annual  Report  before  investing  in our common
stock.  Our business and results of operations  could be seriously harmed by any
of the following risks.

                                       4
<PAGE>
RISKS RELATED TO OUR BUSINESS

OUR  INDEPENDENT  AUDITOR  HAS RAISED  DOUBT  ABOUT OUR ABILITY TO CONTINUE AS A
GOING CONCERN.

     The Independent  Auditor's Report to our audited  financial  statements for
the year ended  December 31, 2007,  included in this Form 10-K,  indicates  that
there are a number of factors that raise  substantial doubt about our ability to
continue as a going  concern.  Such doubts  identified in the report include the
fact that we currently have no source of revenue and we need to obtain  adequate
financing.  If we are not able to continue as a going concern, it is likely that
investors will lose all or a part of their investment.

WE ARE SERIOUSLY UNDERCAPITALIZED AND HAVE LIMITED LIQUIDITY.

     Historically,  Cavit has financed its operations primarily from the sale of
its equity securities.  As of December 31, 2007, Cavit had cash of approximately
$ 15,000.  Our current burn rate is  approximately  $50,000 per month  excluding
capital expenditures.  As a result of expected financing, Cavit believes that it
has sufficient  working capital to fund  operations  through the end of calendar
2008.  Thereafter,  Cavit  will  need to raise  additional  capital  to fund its
working  capital  needs.  Cavit  does  not have any  material  commitments  from
investors or any credit facilities available with financial  institutions or any
other third  parties.  Therefore,  it is expected  that Cavit will need to enter
into agreements with investors or engage in best efforts sales of its securities
to  raise  needed  working  capital.  There  is no  assurance  that  we  will be
successful  in any  funding  effort.  The  failure  to  raise  such  funds  will
necessitate  the  curtailment  of  operations  and  delay  of the  start  of any
additional testing.

 WE DO NOT HAVE AN INDEPENDENT AUDIT OR COMPENSATION COMMITTEE.

     Our audit and  compensation  committees are made up of members of our board
of directors and are, therefore,  not considered independent.  The absence of an
independent audit and compensation committee could lead to conflicts of interest
between committee members and our officers and directors,  which could work as a
detriment to our shareholders.

WE ARE A DEVELOPMENT STAGE COMPANY AND WE HAVE NO SIGNIFICANT OPERATING HISTORY.

     We are a development stage company that has not had prior  operations.  See
"Management's  Plan  of  Operations  -  Patent   Acquisition   Information"  and
"Description of Business - History of Intellectual  Property  Rights" for a more
detailed discussion of prior operations. Our plans and businesses are "proposed"
and  "intended,"  but we may not be able to  successfully  implement  them.  Our
primary  business  purposes are to collaborate  with and market our intellectual
property   rights  to  major  drug  companies  and  to   commercialize   premium
supplements.  As  of  the  date  of  this  prospectus,  we  have  twelve  patent
applications  and  two  developed  supplement  lines.  However,  the FDA has not
approved any of our drugs for sale in the United States,  none of our drugs have
been  approved  for sale by any  foreign  country,  our  supplements  are  being
manufactured,  but have not yet  been  sold.  In  addition,  we have not  earned
revenues and have  incurred  losses since our  incorporation  in April 2006.  We
currently lack sufficient capital to generate revenue or operate our business in
a profitable  manner. As a development stage company,  our prospects are subject

                                       5
<PAGE>
to all of the risks,  expenses,  and  uncertainties  frequently  encountered  by
companies in the drug development and pharmaceutical  business.  In addition, we
are subject to all of the risks, uncertainties,  expenses, delays, problems, and
difficulties  typically  encountered in the establishment of a new business.  We
expect that unanticipated  expenses,  problems,  and technical difficulties will
occur and that they will result in  material  delays in the  development  of our
products. We may not obtain sufficient capital or achieve a significant level of
operations  and, even if we do, we may not be able to conduct such operations on
a profitable basis.

IF WE DO NOT  SUCCESSFULLY  COMMERCIALIZE  OUR  PRODUCTS,  WE MAY NEVER  ACHIEVE
PROFITABILITY.

     We  have  never  commercially   introduced  a  product.  Our  research  and
development  programs  are at an early  stage.  Potential  drug  candidates  are
subject to inherent risks of failure. These risks include the possibilities that
no drug candidate will be found safe or effective,  meet  applicable  regulatory
standards or receive necessary  regulatory  clearances.  Even safe and effective
drug candidates may never be developed into commercially successful drugs. If we
are unable to develop  safe,  commercially  viable  drugs,  we may never achieve
profitability and if we become profitable, we may not remain profitable.

AS A RESULT OF OUR INTENSELY COMPETITIVE INDUSTRY, WE MAY NOT GAIN ENOUGH MARKET
SHARES TO BE PROFITABLE.

     The  biotechnology,  pharmaceutical  and  food  supplement  industries  are
intensely  competitive.  We have numerous  competitors  in the United States and
elsewhere.  Because we are pursuing  potentially large markets,  our competitors
include major, multinational pharmaceutical and chemical companies,  specialized
biotechnology firms,  universities and other research  institutions.  Several of
these competitors have already successfully marketed and commercialized products
that will compete with our products,  assuming that our products gain regulatory
approval.

     Most of our competitors have greater financial  resources,  larger research
and  development   staffs  and  more  effective   marketing  and   manufacturing
organizations than we do. In addition, academic and government institutions have
become  increasingly  aware of the commercial value of their research  findings.
These  institutions  are now more  likely  to  enter  into  exclusive  licensing
agreements with commercial  enterprises,  including our competitors,  to develop
and market commercial products.

     Our  competitors  may succeed in developing or licensing  technologies  and
drugs that are more  effective  or less costly than any we are  developing.  Our
competitors may succeed in obtaining FDA or other regulatory  approvals for drug
candidates before we do. If competing drug candidates prove to be more effective
or less costly than our drug candidates,  our drug candidates,  even if approved
for sale, may not be able to compete successfully with our competitors' existing
products  or  new  products  we  may  develop.  If  we  are  unable  to  compete
successfully,  we will not be able to sell enough products at a price sufficient
to permit us to generate profits.

                                       6
<PAGE>
EXISTING  PRICING  REGULATIONS  AND  REIMBURSEMENT  LIMITATIONS  MAY  REDUCE OUR
POTENTIAL PROFITS FROM THE SALE OF OUR PRODUCTS.

     The requirements  governing  product  licensing,  pricing and reimbursement
vary widely from country to country. Some countries require approval of the sale
price of a drug before it can be marketed. In many countries, the pricing review
period begins after  product-licensing  approval is granted. As a result, we may
obtain  regulatory  approval for a drug candidate in a particular  country,  but
then be subject to price  regulations  that reduce our profits  from the sale of
the product. In some foreign markets, pricing of prescription pharmaceuticals is
subject to continuing  government control even after initial marketing approval.
In  addition,   certain  governments  may  grant  third  parties  a  license  to
manufacture  our  product  without  our  permission.  Such  compulsory  licenses
typically  would be on terms  that are less  favorable  to us and would have the
effect of reducing our revenues.

     Varying price regulation between countries can lead to inconsistent  prices
and some re-selling by third parties of products from markets where products are
sold at lower prices to markets where those  products are sold at higher prices.
This practice of exploiting price differences  between countries could undermine
our sales in  markets  with  higher  prices  and  reduce the sales of our future
products,  if any. The decline in the size of the markets in which we may in the
future sell  commercial  products could cause the perceived  market value of our
business  and  the  price  of our  common  stock  to  decline.  Our  ability  to
commercialize  our products  successfully also will depend in part on the extent
to which  reimbursement for the cost of our products and related treatments will
be available from government health administration  authorities,  private health
insurers  and  other   organizations.   Third-party   payers  are   increasingly
challenging the prices charged for medical products and services.  If we succeed
in bringing any of our potential  products to the market,  such products may not
be  considered  cost  effective  and  reimbursement  may  not  be  available  or
sufficient  to allow us to sell such  products on a  profitable  or  competitive
basis.

OUR ABILITY TO ACHIEVE  ANY  SIGNIFICANT  REVENUE  WILL DEPEND ON OUR ABILITY TO
ESTABLISH EFFECTIVE SALES AND MARKETING CAPABILITIES.

     Our efforts to date have focused on the  development  and evaluation of our
drug   candidates.   As  we   conduct   clinical   studies   and   prepare   for
commercialization  of our drug  candidates,  we may  need to  build a sales  and
marketing  infrastructure.  As a company, we have no experience in the sales and
marketing  of  pharmaceutical  products.  If we fail to  establish a  sufficient
marketing  and  sales  force  or to make  alternative  arrangements  to have our
products  marketed and sold by others on  attractive  terms,  it will impair our
ability  to  commercialize  our drug  candidates  and to enter  new or  existing
markets.  Our inability to effectively  enter these markets would materially and
adversely affect our ability to generate significant revenues.

WE DEPEND HEAVILY ON MANAGEMENT TEAM AND CONSULTANTS.

     Our business  strategy and success is dependent on the skills and knowledge
of our management  team.  Our operations  will also be dependent on the efforts,
ability and experience of key members of our  prospective  management  staff. We
also operate with a small number of advisors  and  consultants  and,  therefore,
have little backup capability for their activities.  The loss of services of one

                                       7
<PAGE>
or  more  members  of our  management  team  or the  loss  of one or more of our
advisors could weaken  significantly our management expertise and our ability to
efficiently run our business. We do not maintain key man life insurance policies
on any of our officers,  although we intend to obtain such insurance policies in
the future.

WE MAY  FACE  PRODUCT  LIABILITY  CLAIMS  RELATED  TO THE USE OR  MISUSE  OF OUR
PRODUCTS, WHICH MAY CAUSE US TO INCUR SIGNIFICANT LOSSES.

     We  may  be  exposed  to  the  risk  of  product  liability  claims  due to
administration  of our drug candidates in our clinical trials,  since the use or
misuse of our drug candidates during a clinical trial could  potentially  result
in injury or death. If we are able to commercialize  our products,  we will also
be subject to the risk of losses in the future due to product  liability  claims
in the event that the use or misuse of our commercial products results in injury
or death.  We  currently do not maintain  liability  insurance.  In the event we
choose to purchase liability  insurance,  we cannot predict the magnitude or the
number of claims that may be brought against us in the future.  Accordingly,  we
do not know what coverage  limits would be adequate.  In addition,  insurance is
expensive,  difficult  to  obtain  and may not be  available  in the  future  on
acceptable  terms or at all. Any claims  against us,  regardless of their merit,
could substantially increase our costs and cause us to incur significant losses.

THE  MARKETABILITY  AND  PROFITABILITY  OF OUR  PRODUCTS  IS  SUBJECT TO UNKNOWN
ECONOMIC CONDITIONS.

     The  marketability  and  profitability  of our  products  may be  adversely
affected by local,  regional,  national and  international  economic  conditions
beyond our control and/or the control of our management.  Favorable  changes may
not necessarily enhance the marketability or profitability of the products. Even
under the most favorable  marketing  conditions,  there is no guarantee that our
products  can be sold or, if sold,  that  such sale will be made upon  favorable
prices and terms.

RISKS RELATED TO OUR INTELLECTUAL PROPERTY

IF WE FAIL TO PROTECT OUR PROPRIETARY TECHNOLOGY,  THEN OUR COMPETITIVE POSITION
WILL BE IMPAIRED.

     We have  obtained  and are in the process of  obtaining  United  States and
foreign patent applications for our products. Our success will depend in part on
our ability to obtain additional United States and foreign patent protection for
our drug  candidates  and  processes,  preserve  our trade  secrets  and operate
without  infringing  the  proprietary  rights of others.  We place  considerable
importance on obtaining  patent  protection for  significant  new  technologies,
products  and  processes.  Legal  standards  relating to the validity of patents
covering  pharmaceutical  and  biotechnology  inventions and the scope of claims
made under such patents are still developing.  In some of the countries in which
we intend to market our products,  pharmaceuticals  are either not patentable or
have only recently become patentable.  Past enforcement of intellectual property
rights in many of these  countries  has been  limited  or  non-existent.  Future
enforcement  of patents and  proprietary  rights in many other  countries may be
problematic or unpredictable.  Moreover, the issuance of a patent in one country

                                       8
<PAGE>
does not assure the  issuance  of a similar  patent in  another  country.  Claim
interpretation and infringement laws vary by nation, so the extent of any patent
protection  is uncertain and may vary in different  jurisdictions.  Our domestic
patent position is also highly  uncertain and involves complex legal and factual
questions.  The  applicant  or  inventors  of subject  matter  covered by patent
applications or patents owned by us may not have been the first to invent or the
first to file patent  applications  for such  inventions.  Due to  uncertainties
regarding patent law and the circumstances  surrounding our patent applications,
the pending or future patent  applications we own may not result in the issuance
of any  patents.  Existing  or  future  patents  owned by us may be  challenged,
infringed  upon,  invalidated,  found to be  unenforceable  or  circumvented  by
others. Further, any rights we may have under any issued patents may not provide
us with sufficient  protection against  competitive  products or otherwise cover
commercially valuable products or processes.

LITIGATION OR OTHER DISPUTES  REGARDING PATENTS AND OTHER PROPRIETARY RIGHTS MAY
BE EXPENSIVE,  CAUSE DELAYS IN BRINGING  PRODUCTS TO MARKET AND HARM OUR ABILITY
TO OPERATE.

     The manufacture, use, marketing or sale of our drug candidates may infringe
on the patent rights of others.  If we are unable to avoid  infringement  of the
patent  rights  of  others,  we may be  required  to seek a  license,  defend an
infringement  action or challenge  the validity of the patents in court.  Patent
litigation is costly and time consuming. We may not have sufficient resources to
bring these actions to a successful conclusion. In addition, if we do not obtain
a license, develop or obtain non-infringing  technology, or fail to successfully
defend an  infringement  action or have the  patents we are  alleged to infringe
declared invalid, we may:

     *    incur substantial money damages;
     *    encounter  significant  delays  in  bringing  our drug  candidates  to
          market;
     *    be precluded from participating in the manufacture, use or sale of our
          drug  candidates  or  methods of  treatment  without  first  obtaining
          licenses to do so; and/or
     *    not be able to obtain any required  license on favorable  terms, if at
          all.

     In addition,  if another  party  claims the same subject  matter or subject
matter  overlapping  with the subject  matter  that we have  claimed in a United
States patent application or patent, we may decide or be required to participate
in interference  proceedings in the United States Patent and Trademark Office in
order to  determine  the  priority of  invention.  Loss of such an  interference
proceeding would deprive us of patent protection  sought or previously  obtained
and could prevent us from  commercializing  our products.  Participation in such
proceedings  could  result in  substantial  costs,  whether or not the  eventual
outcome  is  favorable.  These  additional  costs  could  adversely  affect  our
financial results.

CONFIDENTIALITY  AGREEMENTS WITH EMPLOYEES AND OTHERS MAY NOT ADEQUATELY PREVENT
DISCLOSURE OF TRADE SECRETS AND OTHER PROPRIETARY INFORMATION.

     In order to protect our proprietary technology and processes,  we also rely
in part on confidentiality agreements with our employees,  consultants,  outside
scientific  collaborators  and sponsored  researchers and other advisors.  These
agreements may not effectively  prevent  disclosure of confidential  information
and may not provide an adequate remedy in the event of  unauthorized  disclosure
of confidential  information.  In addition,  others may  independently  discover
trade secrets and proprietary information.  Costly and time-consuming litigation

                                       9
<PAGE>
could be necessary to enforce and determine the scope of our proprietary  rights
and failure to obtain or maintain trade secret protection could adversely affect
our competitive business position.

RISKS RELATED TO OUR INDUSTRY

WE MUST OBTAIN  GOVERNMENT  REGULATORY  APPROVAL FOR OUR PRODUCTS  BEFORE WE CAN
SELL THEM AND GENERATE REVENUES.

     Our principal  development  efforts are currently  centered around research
and development of drugs for treatment of cancer and viral infections.  However,
all drug candidates require FDA and foreign government approvals before they can
be commercialized in the U.S. or in foreign countries.  These regulations change
from  time to  time  and  new  regulations  may be  adopted.  None  of our  drug
candidates  has been approved for  commercial  sale.  We will incur  significant
operating  losses  over  the next few  years  as we fund  development,  clinical
testing and other  expenses  while seeking  regulatory  approval.  While limited
clinical trials of our drug candidates have been conducted to date,  significant
additional  trials are required and we may not be able to demonstrate that these
drug  candidates  are safe or  effective.  If we are unable to  demonstrate  the
safety and  effectiveness  of a particular drug candidate to the satisfaction of
regulatory  authorities,  the drug candidate will not obtain required government
approval.  If we do not receive FDA or foreign  approvals for our drug products,
we will not be able to sell our drug products and will not generate revenues. If
we receive  regulatory  approval of a drug  product,  such  approval  may impose
limitations  on the  indicated  uses for which we may market  the drug,  further
limiting our ability to generate significant revenues.

AS A RESULT OF OUR INTENSELY COMPETITIVE INDUSTRY, WE MAY NOT GAIN ENOUGH MARKET
SHARES TO BE PROFITABLE.

     The  biotechnology,  pharmaceutical  and  food  supplement  industries  are
intensely  competitive.  We have numerous  competitors  in the United States and
elsewhere.  Because we are pursuing  potentially large markets,  our competitors
include major, multinational pharmaceutical and chemical companies,  specialized
biotechnology firms,  universities and other research  institutions.  Several of
these competitors have already successfully marketed and commercialized products
that will compete with our products,  assuming that our products gain regulatory
approval.

     Most of our competitors have greater financial  resources,  larger research
and  development   staffs  and  more  effective   marketing  and   manufacturing
organizations than we do. In addition, academic and government institutions have
become  increasingly  aware of the commercial value of their research  findings.
These  institutions  are now more  likely  to  enter  into  exclusive  licensing
agreements with commercial  enterprises,  including our competitors,  to develop
and market commercial products.

     Our  competitors  may succeed in developing or licensing  technologies  and
drugs that are more  effective  or less costly than any we are  developing.  Our
competitors may succeed in obtaining FDA or other regulatory  approvals for drug
candidates before we do. If competing drug candidates prove to be more effective
or less costly than our drug candidates,  our drug candidates,  even if approved
for sale, may not be able to compete successfully with our competitors' existing

                                       10
<PAGE>
products  or  new  products  we  may  develop.  If  we  are  unable  to  compete
successfully,  we will not be able to sell enough products at a price sufficient
to permit us to generate profits.

EXISTING  PRICING  REGULATIONS  AND  REIMBURSEMENT  LIMITATIONS  MAY  REDUCE OUR
POTENTIAL PROFITS FROM THE SALE OF OUR PRODUCTS.

     The requirements  governing  product  licensing,  pricing and reimbursement
vary widely from country to country. Some countries require approval of the sale
price of a drug before it can be marketed. In many countries, the pricing review
period begins after  product-licensing  approval is granted. As a result, we may
obtain  regulatory  approval for a drug candidate in a particular  country,  but
then be subject to price  regulations  that reduce our profits  from the sale of
the product. In some foreign markets, pricing of prescription pharmaceuticals is
subject to continuing  government control even after initial marketing approval.
In  addition,   certain  governments  may  grant  third  parties  a  license  to
manufacture  our  product  without  our  permission.  Such  compulsory  licenses
typically  would be on terms  that are less  favorable  to us and would have the
effect of reducing our revenues.

     Varying price regulation between countries can lead to inconsistent  prices
and some re-selling by third parties of products from markets where products are
sold at lower prices to markets where those  products are sold at higher prices.
This practice of exploiting price differences  between countries could undermine
our sales in  markets  with  higher  prices  and  reduce the sales of our future
products,  if any. The decline in the size of the markets in which we may in the
future sell  commercial  products could cause the perceived  market value of our
business  and  the  price  of our  common  stock  to  decline.  Our  ability  to
commercialize  our products  successfully also will depend in part on the extent
to which  reimbursement for the cost of our products and related treatments will
be available from government health administration  authorities,  private health
insurers  and  other   organizations.   Third-party   payers  are   increasingly
challenging the prices charged for medical products and services.  If we succeed
in bringing any of our potential  products to the market,  such products may not
be  considered  cost  effective  and  reimbursement  may  not  be  available  or
sufficient  to allow us to sell such  products on a  profitable  or  competitive
basis.

OUR PRODUCTS IN DEVELOPMENT  WILL BE SUBJECT TO  REIMBURSEMENT  FROM  GOVERNMENT
AGENCIES  AND OTHER THIRD  PARTIES.  PHARMACEUTICAL  PRICING  AND  REIMBURSEMENT
PRESSURES MAY REDUCE PROFITABILITY.

     Successful  commercialization  of our  products  depends,  in part,  on the
availability of governmental and third party payer reimbursement for the cost of
such  products  and  related   treatments.   Government  health   administration
authorities,  private health insurers and other organizations  generally provide
reimbursement.  Government  authorities and third-party payers  increasingly are
challenging  the  price of  medical  products  and  services,  particularly  for
innovative new products and therapies.  This has resulted in lower average sales
prices.  Our  business  may be  adversely  affected  by an  increase  in U.S. or
international  pricing  pressures.  These  pressures  can arise  from  rules and
practices of managed care groups,  judicial  decisions and governmental laws and
regulations related to Medicare, Medicaid and health care reform, pharmaceutical
reimbursement  and pricing in general.  New legislation has been proposed at the

                                       11
<PAGE>
federal and state levels that would effect major changes in the U.S. health care
system,  either nationally or at the state level.  These proposals have included
prescription drug benefit proposals for Medicare  beneficiaries  recently passed
by  Congress.   Additionally,  some  states  have  enacted  health  care  reform
legislation. Further federal and state developments are possible. Our results of
operations could be adversely affected by future health care reforms. In Europe,
the  success  of  our  products  will  also  depend  largely  on  obtaining  and
maintaining  government   reimbursement  because  in  many  European  countries,
including  the United  Kingdom and France,  patients  are  reluctant  to pay for
prescription  drugs out of their own pocket.  We also expect that the success of
our products in development,  particularly in Europe, will depend on the ability
to obtain  reimbursement.  Even if  reimbursement  is  available,  reimbursement
policies may  adversely  affect our ability to sell our products on a profitable
basis.

     Delays in the conduct or completion of our preclinical or clinical  studies
or the analysis of the data from our preclinical or clinical  studies may result
in delays in our planned  filings for regulatory  approvals or adversely  affect
our ability to enter into collaborative arrangements.

     *    We may encounter problems with some or all of our completed or ongoing
          studies  that  may  cause  us or  regulatory  authorities  to delay or
          suspend  our  ongoing  studies or delay the  analysis of data from our
          completed or ongoing studies.
     *    We rely,  in part,  on third  parties  to  assist us in  managing  and
          monitoring our preclinical and clinical studies. Our reliance on these
          third  parties  may  result in  delays in  completing  or  failure  to
          complete studies if third parties fail to perform their obligations to
          us.

RESULTS  OF  CLINICAL  TRIALS  ARE  UNCERTAIN  AND  MAY  NOT  SUPPORT  CONTINUED
DEVELOPMENT OF A PRODUCT  PIPELINE,  WHICH WOULD ADVERSELY  AFFECT OUR PROSPECTS
FOR FUTURE REVENUE GROWTH.

     We are required to demonstrate the safety and  effectiveness of products we
develop in each intended use through extensive  preclinical studies and clinical
trials.  The results from  preclinical and early clinical  studies do not always
accurately  predict  results  in  later,   large-scale   clinical  trials.  Even
successfully  completed large-scale clinical trials may not result in marketable
products.  A number of  companies  in our  industry  have  suffered  setbacks in
advanced  clinical trials despite promising results in earlier trials. If any of
our  products  under  development  fail to achieve  their  primary  endpoint  in
clinical  trials  or if  safety  issues  arise,  commercialization  of that drug
candidate could be delayed or halted.

RISKS RELATED TO AN INVESTMENT IN OUR SECURITIES

OUR COMMON STOCK IS CONSIDERED  TO BE A "PENNY  STOCK" AND, AS SUCH,  THE MARKET
FOR OUR COMMON STOCK MAY BE FURTHER  LIMITED BY CERTAIN SEC RULES  APPLICABLE TO
PENNY STOCKS.

     As long as the price of our common stock  remains  below $5.00 per share or
we have net tangible  assets of $2,000,000  or less,  our shares of common stock
are likely to be subject to certain "penny stock" rules  promulgated by the SEC.
Those rules impose certain sales practice requirements on brokers who sell penny
stock to persons  other than  established  customers  and  accredited  investors
(generally,  an institution with assets in excess of $5,000,000 or an individual

                                       12
<PAGE>
with a net worth in excess of $1,000,000). For transactions covered by the penny
stock rules, the broker must make a special  suitability  determination  for the
purchaser and receive the purchaser's  written consent to the transaction  prior
to the sale.  Furthermore,  the penny stock rules generally require, among other
things,  that  brokers  engaged in  secondary  trading of penny  stocks  provide
customers with written  disclosure  documents,  monthly statements of the market
value of penny stocks,  disclosure of the bid and asked prices and disclosure of
the  compensation  to the  brokerage  firm and  disclosure  of the sales  person
working  for the  brokerage  firm.  These  rules  and  regulations  make it more
difficult for brokers to sell shares of our common stock and limit the liquidity
of our shares. See "Plan of Distribution" for a more detailed  discussion of the
penny stock rules and related broker-dealer restrictions.

TRADING IN OUR SECURITIES  COULD BE SUBJECT TO EXTREME PRICE  FLUCTUATIONS  THAT
COULD ADVERSELY AFFECT YOUR INVESTMENT.

     The market prices for securities of biotechnology  companies,  particularly
those that are not profitable,  have been highly volatile,  especially recently.
Publicized events and announcements may have a significant  impact on the market
price of our common stock. For example, any of the following may have the effect
of temporarily or permanently driving down the price of our common stock:

     *    Biological or medical discoveries by competitors;
     *    Public concern about the safety of our drug candidates;
     *    Delays in the conduct or analysis of our clinical trials;
     *    Unfavorable results from clinical trials;
     *    Unfavorable  developments  concerning  patents  or  other  proprietary
          rights; or
     *    Unfavorable domestic or foreign regulatory developments;

     In addition,  the stock market from time to time experiences  extreme price
and volume fluctuations which particularly affect the market prices for emerging
and life sciences companies,  such as ours, and which are often unrelated to the
operating performance of the affected companies.

SUBSTANTIAL SALES OF OUR STOCK MAY IMPACT THE MARKET PRICE OF OUR COMMON STOCK.

     Future sales of substantial  amounts of our common stock,  including shares
that we may issue upon exercise of options and warrants,  could adversely affect
the market price of our common  stock.  Further,  if we raise  additional  funds
through  the  issuance  of  common  stock  or  securities  convertible  into  or
exercisable for common stock, the percentage  ownership of our shareholders will
be reduced and the price of our common stock may fall.

                                       13
<PAGE>
WE DO NOT EXPECT TO PAY DIVIDENDS FOR THE FORESEEABLE FUTURE.

     We will use any  earnings  generated  from our  operations  to finance  our
business  and  will  not pay  any  cash  dividends  to our  shareholders  in the
foreseeable future.

ISSUING  PREFERRED  STOCK WITH RIGHTS  SENIOR TO THOSE OF OUR COMMON STOCK COULD
ADVERSELY AFFECT HOLDERS OF COMMON STOCK.

     Our charter  documents  give our board of directors  the authority to issue
series of  preferred  stock  without a vote or action by our  shareholders.  The
board  also  has the  authority  to  determine  the  terms of  preferred  stock,
including price, preferences and voting rights. The rights granted to holders of
preferred stock may adversely  affect the rights of holders of our common stock.
For example,  a series of preferred  stock may be granted the right to receive a
liquidation  preference - a pre-set  distribution  in the event of a liquidation
that would reduce the amount  available  for  distribution  to holders of common
stock. In addition, the issuance of preferred stock could make it more difficult
for a third party to acquire a majority of our  outstanding  voting stock.  As a
result,   common   shareholders   could  be  prevented  from   participating  in
transactions that would offer an optimal price for their shares.

RISKS ASSOCIATED WITH FORWARD-LOOKING STATEMENTS

     This  Form  10-K  contains  certain  forward-looking  statements  regarding
management's  plans and objectives  for future  operations  including  plans and
objectives  relating  to our  planned  marketing  efforts  and  future  economic
performance.  The  forward-looking  statements and associated risks set forth in
this Form 10-K include or relate to, among other things, (a) our projected sales
and  profitability,  (b) our growth  strategies,  (c) anticipated  trends in our
industry,  (d) our  ability to obtain and retain  sufficient  capital for future
operations,  and (e) our anticipated needs for working capital. Actual events or
results may differ materially from those discussed in forward-looking statements
as a result  of  various  factors,  including,  without  limitation,  the  risks
outlined  under  "Risk  Factors"  and  matters  described  in  this  prospectus,
generally. In light of these risks and uncertainties,  there can be no assurance
that the forward-looking  statements  contained in this Form 10-K will, in fact,
occur.

REPORTS TO SECURITY HOLDERS

     The public may view and obtain  copies of the Company's  reports,  as filed
with the Securities and Exchange Commission,  at the SEC's Public Reference Room
(Room 1580) at 100 F Street, N.E.,  Washington,  D.C. 20549.  Information on the
Public  Reference  Room is  available  by  calling  the SEC at  (202)  551-8090.
Additionally,  copies of the Company's reports are available and can be accessed
and   downloaded   via   the   internet   on  the   SEC's   internet   site   at
http://www.sec.gov/cgi-bin/srch-edgar,  by simply  typing  in  "Cavit  Sciences,
Inc." Additional Company information is available on the Company's internet site
at http://www.cavitsciences.com.

                                       14
<PAGE>
ITEM 2. PROPERTIES.

     Commencing on January 1, 2008,  we relocated  our  principal  executive and
administrative offices to 20 NW 181st Street, Miami, Florida 33169, the building
where we have our  manufacturing  and research and development  facilities.  Our
telephone number is (305) 493-3304. We are currently leasing approximately 2,300
square feet at this  location  at monthly  rental of $5,337.  Our current  lease
expires  December  31,  2008 and we have the  option to renew the lease for five
additional  one year  periods at the current base rent plus 10% for each year of
the extended term.

     During 2007, our principal executive and administrative office facility was
located in Delray Beach,  Florida at 100 East Linton Blvd.,  Suite 106B,  Delray
Beach,  Florida  33483.  We  terminated  our lease on the Delray Beach  facility
effective January 31, 2008.

ITEM. 3 LEGAL PROCEEDINGS.

     The  Company is not the  subject of any pending  legal  proceedings  to the
knowledge of  management,  nor is there any presently  contemplated  against the
Company by any federal, state, or local government agency.

     Further,  to the knowledge of management,  no director or executive officer
is a party to any action in which his interest is adverse to the Company.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

None.

                                     PART II

ITEM 5. MARKET  FOR  COMMON  EQUITY,  RELATED  STOCKHOLDER  MATTERS  AND ISSUER
        PURCHASES OF EQUITY SECURITIES.

     As of the date of this Annual Report,  the Company's Common Stock is quoted
on the  Over-the-Counter  Bulletin Board under the symbol  "CVIT.OB." The market
for the Company's  Common Stock is limited,  volatile and sporadic and the price
of the Company's Common Stock could be subject to wide  fluctuations in response
to  quarterly  variations  in operating  results,  news  announcements,  trading
volume, sales of Common Stock by officers,  directors and principal shareholders
of the Company,  general market trends, changes in the supply and demand for the
Company's shares, and other factors. The following table sets forth the high and
low sales prices for each quarter relating to the Company's Common Stock for the
last two fiscal years.  The  Company's  Common Stock was not quoted or traded on
any exchange until the fourth quarter of 2006.

                 Fiscal 2007                  High        Low
                 -----------                  ----        ---
                 First Quarter (1)           $ .55       $ .07
                 Second Quarter (1)          $ .47       $ .14
                 Third Quarter (1)           $ .75       $ .25
                 Fourth Quarter (1)          $ .95       $ .31

                 Fiscal 2006                  High        Low
                 -----------                  ----        ---
                 First Quarter (1)           $  --       $  --
                 Second Quarter (1)          $  --       $  --
                 Third Quarter (1)           $  --       $  --
                 Fourth Quarter (1)          $ .60       $ .25

                                       15
<PAGE>
----------
(1)  This represents the high and low quote information for the stock on the OTC
     Bulletin Board. The bid and ask quotations represent prices between dealers
     and do not  include  retail  markup,  markdown or  commission.  They do not
     represent  actual  transactions  and  have  not  been  adjusted  for  stock
     dividends or splits.

     All of the  above  information  was  listed  as  reported  by the  National
Association of Securities Dealers Composite feed or other qualified inter-dealer
quotation medium.

HOLDERS

     As of April 10, 2008, there were  approximately  242 shareholders of record
of the Company's Common Stock.

DIVIDENDS

     The Company has not declared any cash  dividends with respect to its common
stock or preferred stock during the last two fiscal years and does not intend to
declare dividends in the foreseeable future. There are no material  restrictions
limiting or that are likely to limit the  Company's  ability to pay dividends on
its outstanding securities.

     For information regarding the Company's Equity Compensation Plans, see Part
III, Item 11.

RECENT ISSUANCE OF UNREGISTERED SECURITIES

     Since its  incorporation  on April 12, 2006, Cavit has issued the following
securities without registration under the Securities Act of 1933:

<TABLE>
<CAPTION>
                           Number of             Aggregate                Nature of
Date of Issuance         Shares Issued       Sales Price (Value)        Transaction
----------------         -------------       -------------------        -----------
<S>                      <C>                <C>                       <C>
April 12, 2006              100,000             $   1,000             Director Fees
May 1, 2006                 200,000             $   2,000             Director Fees
May 1, 2006                  50,000             $     500             Executive Compensation
May 12, 2006                 37,500             $   3,000             Private Offering
May 24, 2006                300,000             $  24,000             Private Offering
May 24, 2006                200,000             $  16,000             Legal Services
May 25, 2006                150,000             $  12,000             Private Offering
May 31, 2006              8,475,000             $ 145,459             Acquisition of patent application rights
                                                                      from then parent corporation
June 14, 2006               750,000             $  60,000             Private Offering
June 29, 2006                55,000             $   4,400             Consulting Fees
June 30, 2006               200,000             $  16,000             Director Fees
October 17, 2006            100,000             $   8,000             Consulting Fees
November 13, 2006           762,500             $  61,000             Private Offering
November 13, 2006           200,000             $  16,000             Consulting Fees
November 24, 2006           115,800             $   9,264             Transfer Agent Services
</TABLE>

                                       16
<PAGE>
<TABLE>
<CAPTION>
<S>                      <C>                <C>                       <C>
December 1, 2006            375,000             $  30,000             Private offering
December 7, 2006            187,500             $  15,000             Executive Compensation (CFO)
December 15, 2006           187,500             $  15,000             Directors Fees
December 15, 2006           187,500             $  15,000             Executive Bonus (CEO)
December 15, 2006           187,500             $  15,000             Executive Bonus (CFO)
December 15, 2006           258,807             $  20,705             Anti-dilution shares issued to investors
April 25, 2007              166,670             $  15,000             Directors Fees
May 21, 2007                103,449             $  30,000             Executive Compensation (CFO)
May 21, 2007                 50,000             $  14,500             Executive Compensation (CEO)
May 21, 2007                 21,407             $   6,337             Transfer Agent Services
June 26, 2007                42,860             $  15,000             Director Fees
June 26, 2007               109,430             $  50,338             Anti-dilution shares issued to investors
September 20, 2007           37,500             $  15,000             Directors Fees
October 8, 2007               2,304             $   1,382             Transfer Agent Services
October 25, 2007              8,100             $   5,265             Anti-dilution shares issued to investors
December 17, 2007         2,564,839             $ 205,187             Conversion of Notes
January 15, 2008          2,500,000             $ 500,000             Private Offering
January 15, 2008             51,953             $  28,156             Transfer Agent Services
</TABLE>

     Cavit believes that all of the above  transactions  were  transactions  not
involving  any  public  offering  within  the  meaning  of  Section  4(2) of the
Securities Act of 1933, as amended,  since (a) each of the transactions involved
the offering of such  securities to a  substantially  limited number of persons;
(b) each person took the securities as an investment for his/her/its own account
and not with a view to  distribution;  (c) each person had access to information
equivalent  to that which would be included in a  registration  statement on the
applicable  form under the Securities  Act of 1933, as amended;  (d) each person
had knowledge and experience in business and financial matters to understand the
merits and risks of the investment; and (e) appropriate restrictive legends were
placed on all stock certificates. Therefore, no registration statement needed to
be in effect prior to such issuances.

     The Company did not utilize or engage a principal underwriter in connection
with any of the above securities transactions.

     On October 26, 2007,  Cavit issued a series of Class H warrants to purchase
Cavit common stock to four of its original  investors in consideration  for said
four investors forever waiving their anti-dilution rights with respect to future
issuances of Cavit common stock. The names of the Class H warrant  holders,  the
number of shares of common stock  covered by the Class H warrants,  the exercise
price of the  Class H  warrants  and the  term of the  Class H  warrants  are as
follows:

 Name of Holder     Number of Shares Covered     Exercise Price        Term
 --------------     ------------------------     --------------        ----
Raymond Bazley              100,000                  $ .55         Sixty months
Cortland Fund, LLC          100,000                  $ .55         Sixty months
Margaret Smyth              100,000                  $ .55         Sixty months
Robert Hennen                13,334                  $ .55         Sixty months

                                       17
<PAGE>
     On January 11,  2008,  Cavit,  acting  pursuant to its  November  29, 2007,
Agreement  with Vision  International  Enterprises,  S.A.  (Exhibit 10.8 to this
Annual Report), issued a series of warrants to purchase Cavit common stock.

     While the majority of the  language,  terms and  conditions  of the various
warrants are identical, the warrants differ in four areas: (i) class designation
of  warrants;  (ii) number of shares of common  stock  covered by the  warrants;
(iii)  exercise  price  of the  warrants  and  (iv)  term of the  warrants.  The
following table explains the differences in the terms of the warrants:

                            Number of
Class of Warrants        Shares Covered     Exercise Price         Term
-----------------        --------------     --------------         ----
        A                   125,000              $ .40        Six months
        B                   125,000              $ .60        Nine months
        C                   125,000              $ .80        Twelve months
        D                   175,000              $1.00        Fifteen months
        E                   175,000              $1.25        Eighteen months
        F                   175,000              $1.50        Twenty-one months
        G                   175,000              $1.75        Twenty-four months
        I                   250,000              $2.00        Thirty-six months
        J                   175,000              $3.00        Forty-eight months

     On January 11,  2008,  Cavit,  acting  pursuant to its  November  29, 2007,
Agreement with Isthmus Investments Management, S.A. (Exhibit 10.9 to this Annual
Report), issued a series of warrants to purchase Cavit common stock.

     While the majority of the  language,  terms and  conditions  of the various
warrants are identical, the warrants differ in four areas: (i) class designation
of  warrants;  (ii) number of shares of common  stock  covered by the  warrants;
(iii) exercise price of the warrants and (iv) term of the warrants.

     The following table explains the differences in the terms of the warrants:

                            Number of
Class of Warrants        Shares Covered     Exercise Price         Term
-----------------        --------------     --------------         ----
        A                   125,000              $ .40        Six months
        B                   125,000              $ .60        Nine months
        C                   125,000              $ .80        Twelve months
        D                   175,000              $1.00        Fifteen months
        E                   175,000              $1.25        Eighteen months
        F                   175,000              $1.50        Twenty-one months
        G                   175,000              $1.75        Twenty-four months
        I                   250,000              $2.00        Thirty-six months
        J                   175,000              $3.00        Forty-eight months

     Cavit believes that all of the above  transactions  were  transactions  not
involving  any  public  offering  within  the  meaning  of  Section  4(2) of the
Securities Act of 1933, as amended,  since (a) each of the transactions involved
the offering of such  securities to a  substantially  limited number of persons;
(b) each person took the securities as an investment for his/her/its own account

                                       18
<PAGE>
and not with a view to  distribution;  (c) each person had access to information
equivalent  to that which would be included in a  registration  statement on the
applicable  form under the Securities  Act of 1933, as amended;  (d) each person
had knowledge and experience in business and financial matters to understand the
merits and risks of the investment; and (e) appropriate restrictive legends were
placed on all stock certificates. Therefore, no registration statement needed to
be in effect prior to such issuances.

     The Company did not utilize or engage a principal underwriter in connection
with any of the above securities transactions.

ITEM 6. SELECTED FINANCIAL DATA.

Not applicable.

ITEM 7. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATION.

MANAGEMENT'S PLAN OF OPERATIONS

     The following  discussion of our plan of operations should be read together
with the financial  statements and related notes that are included  elsewhere in
this Form 10-K. This  discussion may contain  forward-looking  statements  based
upon current  expectations  that  involve  risks and  uncertainties.  Our actual
results may differ  materially from those  anticipated in these  forward-looking
statements as a result of various factors, including those set forth under "Risk
Factors," "Disclosure Regarding Forward-Looking Statements" or in other parts of
this Form 10-K.  We undertake no  obligation  to update any  information  in our
forward-looking statements except as required by law.

PATENT ACQUISITION INFORMATION

     Hard to Treat began to internally develop the intellectual  property rights
during  2004,  that  were  acquired  by  Cavit on May 31,  2006,  as part of the
operations of Hard to Treat's biotechnology division.  During 2004, research and
development commenced, which was the foundation for the first patent application
being filed  during  December of 2004.  As a result of  additional  research and
development in 2005, two additional  patent  applications were filed in December
2005.

     The boards of directors of Cavit Sciences and Hard to Treat  determined the
value of the  intangible  assets and  related  costs  acquired  to be  $145,459;
comprised of $56,997 in capitalized  legal fees  associated with the development
of the rights from  inception  and $88,462 of direct  research  and  development
which are  considered  purchased  R&D and have been expensed in the December 31,
2006 financial statements.  The $145,459 carved out cost determined the value of
the intangible  assets.  The acquisition costs do not include $47,060 of certain
overhead  expenses  incurred  by Hard to Treat  during  the  development  of the
intellectual  property  rights from  inception  that began in 2004. The overhead
expenses  of  $47,060  that were not part of the  purchase  price  paid by Cavit
included wages,  rent, phone and other  expenditures that Hard to Treat incurred
to develop the intellectual properties.

                                       19
<PAGE>
     At December 31, 2007 and 2006, due to Financial Accounting  Standards,  the
Company  recorded  impairment  charges of $250,  000 and $86,997,  respectively,
which was  primarily  due to the fact  that  such  assets  and  patents  are not
currently  producing  revenues or cash  flows.  The book value of the assets and
patent  application rights do not reflect the future potential of our supplement
line and patents as the  supplement  line is being  manufactured  and the patent
rights are still in the application phase.

     Cavit was incorporated on April 12, 2006 and acquired intellectual property
rights  from  Hard to  Treat  on May 31,  2006.  In July  2006,  Cavit  acquired
additional rights in some of these  intellectual  property rights,  resulting in
Cavit owning 100% of such rights.

     During 2007, Cavit filed an additional PCT Utility patent application,  six
National Phase applications, and two Continuation-In-Part  applications. Cavit's
intellectual property rights currently consist of twelve patent applications.

OVERVIEW

     We are a  development-stage  company and have a limited operating  history.
Cavit Sciences,  Inc. was formed on April 12, 2006, as a wholly owned subsidiary
of Hard to Treat Diseases, Inc., to acquire certain intellectual property rights
from Hard to Treat Diseases and to develop and market the acquired rights.

     Major drug companies are interested in drugs that are safe and effective in
treating  and  preventing  certain  indications  and  conditions,   have  secure
intellectual  property  rights  and have an  available  source and supply of the
composition. Cavit's board has decided to focus on and to pursue the best course
of action in the interest of patients  and  shareholders.  Testing  performed on
certain  drugs has resulted in patent  applications  and  numerous  intellectual
property  rights  which  are  owned  and  controlled  by  Cavit.  We  intend  to
manufacture, per U.S. FDA specifications, one of the drugs we tested and to file
for U.S. FDA approval for certain cancer and/or viral infection indications.  In
addition  to the  current  utility  rights we own,  Cavit will have a source and
control  of the drug.  Due to the  safety  and  effectiveness  of the drug's use
outside the U.S., Cavit will apply for fast track or priority approval by the U.
S. FDA.

     Our initial plan was to market our  intellectual  property  rights to major
drug  companies.  We have been and are  currently  negotiating  with  other drug
companies regarding securing rights to their drug compositions.  The combination
of our current utility rights and the  acquisition of composition  rights should
allow Cavit to develop market and commercialize these drugs successfully.

     In addition, Cavit acquired a food supplement line during February 2007. As
a result of  agreements  entered into with Daycon  Investors  Associates,  Inc.,
Americare  Nutritional  Division and Dr. Jospeh P. D'Angelo,  Cavit acquired the
foundation of two premium supplement lines which were developed during 2007. The
core products in Cavit's supplement lines will enhance and improve the prostate,
maintain  and  support  the  cardiovascular   system,  and  beneficially  effect
arthritis and  osteoporosis.  Superior results have been attained by individuals
with the use of Cavit's  products.  These proven results are due to the research
and testing of the most  effective  formulas  with  nutrients  that  support and
supplement each other at the optimum dosage of each ingredient. Cavit intends to

                                       20
<PAGE>
manufacture,  market, distribute and commercialize a range of supplements to act
as powerful antioxidants and immune enhancers which have beneficial effects upon
many serious diseases.

     Cavit's  current  facilities  accommodate  its  laboratories,  research and
development,  warehouse and corporate offices. The facilities provide ample room
for the development of the food supplement  lines. The plants  laboratories will
be used for ongoing  research and development of existing  products and products
being  developed with innovation as our trend.  The facilities also  accommodate
Cavit's plant equipment,  staff, and relocated corporate  headquarters and allow
for future expansion.

     The food  supplement  lines are an ideal  match  with our drug  development
process.  In addition to creating a full range biotech  company,  the supplement
line will create a steady  stream of cash flow to support the  commercialization
of our drugs.

     We have not generated  any profits  since our entry into the  biotechnology
business,  have no source of revenues and have  incurred  operating  losses.  We
expect to incur additional  operating losses for the foreseeable  future.  We do
not have any sources of revenues and may not have any in the foreseeable  future
unless we market our rights to a drug company.

Results of Operations  for the year ended December 31, 2007 and the period ended
December 31, 2006.

     Cavit has not had any revenue since its inception on April 12, 2006.

     General and administrative  expenses increased by 36% from $593,000 for the
period ended December 31, 2006 to $805,000 for the year ended December 31, 2007.
General  and  administrative   expenses  consist  of  office  expenses,   wages,
professional  fees and  write-off  of  impaired  intangibles.  The  increase  is
primarily  related to the impact of a full year of  general  and  administrative
expenses coupled with an increase in the write-off of an impaired intangible.

     Other  expenses of $205,187 for the period ended  December 31, 2007 consist
primarily of financing costs of $200,000 due to the Company's  determination and
treatment  of the  conversion  feature in the notes  payable and  related  stock
options.

     The Company reported a net loss of $1,010,236, or $(0.07) per share for the
year ended  December 31, 2007 and a net loss of  $593,000,  or ($0.07) per share
for the period ended December 31, 2006.

     We need to obtain  additional  capital  resources  from  sources  including
equity and/or debt financings, license arrangements, grants and/or collaborative
research  arrangements  in  order  to  develop  products  and  continue  Cavit's
business.  We  need  to  raise  additional  working  capital  in  order  to have
sufficient  working  capital to finance  operations.  Our  current  burn rate is
approximately $50,000 per month excluding capital  expenditures.  The timing and
degree  of  any  future  capital  requirements  will  depend  on  many  factors,
including:

     Research and  development.  We expect to make  investments  in research and
development  in order  to  develop  and  market  our  technology.  Research  and
development  costs will  consist  primarily  of general and  administrative  and

                                       21
<PAGE>
operating  expenses  related to research  and  development  activities.  We will
expense  research  and  development  costs  as  incurred.  Property,  plant  and
equipment for research and development  that has an alternative  future use will
be  capitalized  and the related  depreciation  will be expensed as research and
development costs. We expect our research and development expense to increase as
we continue to invest in the development of our technology.

     General  and  administrative.  General  and  administrative  expenses  will
consist  primarily  of  salaries  and  benefits,  office  expense,  professional
services fees, and other corporate  overhead  costs. We anticipate  increases in
general  and  administrative  expenses as we continue to develop and prepare for
marketing of our technology and supplement lines.

OFF-BALANCE SHEET ARRANGEMENTS

     As of the  date of this  Annual  Report,  the  Company  does  not  have any
off-balance  sheet  arrangements  that have or are  reasonably  likely to have a
current  or future  effect on the  Company's  financial  condition,  changes  in
financial  condition,  revenues or expenses,  results of operations,  liquidity,
capital  expenditures or capital  resources that are material to investors.  The
term "off-balance sheet arrangement" generally means any transaction,  agreement
or other  contractual  arrangement  to which an entity  unconsolidated  with the
Company is a party, under which the Company has (i) any obligation arising under
a guarantee,  contract,  derivative  instrument or variable interest;  or (ii) a
retained or contingent  interest in assets transferred to such entity or similar
arrangement  that serves as credit,  liquidity  or market risk  support for such
assets.

FUTURE COMMITMENTS

     As of the  date of this  Annual  Report,  the  Company  does  not  have any
material  commitments  nor  does  management  anticipate  any  further  material
commitments within the next twelve months.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

     Our financial  statements and supplementary  data may be found beginning at
page F-1.

ITEM 9. CHANGES  IN  AND  DISAGREEMENTS  WITH  ACCOUNTANTS  ON  ACCOUNTING  AND
        FINANCIAL DISCLOSURE.

Not applicable.

ITEM 9A. CONTROLS AND PROCEDURES.

(a) EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES.

     Colm J. King, our Chief Executive Officer,  and Matthew J. Cohen, our Chief
Financial Officer, (i) are responsible for establishing and maintaining adequate
internal control over financial reporting of the Company and (ii) have evaluated

                                       22
<PAGE>
the  effectiveness of our internal control over financial  reporting (as defined
in Rules  13a-15(f) or 15d-15(f)  under the 1934 Act as of the end of the period
covered by this Annual Report ("Evaluation Date"). Based on such evaluation, our
Chief Executive  Officer and Chief Financial Officer have concluded that, as the
Evaluation  Date,  our  disclosure  controls  and  procedures  are  effective in
alerting  them  on a  timely  basis  to  material  information  relating  to  us
(including our consolidated subsidiaries) required to be included in our reports
filed or submitted under the 1934 Act, except as discussed below..

     The  management  of  the  Company  is  responsible  for   establishing  and
maintaining adequate internal control over financial  reporting,  as required by
Sarbanes-Oxley  (SOX)  Section  404  A.  The  Company's  internal  control  over
financial reporting is a process designed under the supervision of the Company's
Chef  Executive  Officer  and Chief  Financial  Officer  to  provide  reasonable
assurance  regarding the reliability of financial  reporting and the preparation
of the Company's  financial  statements for external purposes in accordance with
U.S.generally accepted accounting principles.

     As of December  31, 2007,  management  assessed  the  effectiveness  of the
Company's  internal  control over financial  reporting based on the criteria for
effective  internal  control over  financial  reporting  established in Internal
Control--Integrated   Framework   issued   by  the   Committee   of   Sponsoring
Organizations of the Treadway  Commission ("COSO) and SEC guidance on conducting
such  assessments.  Based on that  evaluation,  they concluded that,  during the
period covered by this report,  such internal  controls and procedures  were not
effective to detect the inappropriate application of US GAAP rules as more fully
described  below.  This was due to  deficiencies  that  existed in the design or
operation  of our internal  control  over  financial  reporting  that  adversely
affected  our  internal  controls  and that  may be  considered  to be  material
weaknesses.

     The matters  involving  internal controls and procedures that the Company's
management  considered  to be material  weaknesses  under the  standards  of the
Public Company  Accounting  Oversight Board were : (1) lack of functioning audit
committee and lack of majority of outside  directors on the  Company's  board of
directors,   resulting  in  ineffective   oversight  in  the  establishment  and
monitoring of required  internal  controls and  procedures,  and, (2) inadequate
segregation of duties  consistent with control  objectives.  The  aforementioned
material  weaknesses were identified by the Company's Chief Financial Officer in
connection  with the audit of our  financial  statements as of December 31, 2007
and communicated the matters to our management.

     Management believes that the material weaknesses set forth in items (1) and
(2) above did not have an affect on the Company's  financial  results.  However,
management believes that the lack of a functioning audit committee and lack of a
majority of outside  directors on the Company's  board of directors could result
in  ineffective  oversight  in the  establishment  and  monitoring  of  required
internal  controls and procedures.  Management's  goals are to have a functional
audit  committee and a majority of outside  directors on the Company's  board of
directors when funds are available.

     This Annual Report does not include an attestation  report of the Company's
registered  public  accounting  firm regarding  internal  control over financial
reporting.  Management's  report was not subject to attestation by the Company's

                                       23
<PAGE>
registered  public accounting firm pursuant to temporary rules of the Securities
and Exchange  Commission  that permit the Company to provide  only  management's
report in this Annual Report.

(b) CHANGES IN INTERNAL CONTROLS.

     In addition, no change in our internal control over financial reporting (as
defined in Rules 13a-15 or 15d-15 under the 1934 Act) occurred during the fourth
quarter of the year ended December 31, 2007, that has materially affected, or is
reasonably  likely to materially  affect,  our internal  control over  financial
reporting.

ITEM 9B. OTHER INFORMATION.

Not applicable.

                                    PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

     Our  executive  officers are elected by the board of directors and serve at
the discretion of the board, subject to employment and/or consulting  agreements
described in Item 11, below.  All of the current  directors serve until the next
annual  shareholders'  meeting or until their  successors have been duly elected
and qualified.  The following table sets forth certain information regarding our
current directors and executive officers:

     Name             Age              Position                   Director Since
     ----             ---              --------                   --------------
Colm J. King          50      President, Chief Executive          April 12, 2006
                              Officer and Director

Raymond S. Bazley     44      Director                             June 30, 2006

Matthew J. Cohen      49      Chief Financial Officer                   N/A

     Certain biographical information of our directors and officers is set forth
below.

     COLM J. KING. Mr. King is also the President and Chief Executive Officer of
Hard to Treat Diseases, Inc, having been elected to those offices on October 30,
2003. From January 2003 until October 2003, Mr. King worked for Berkovits,  Lago
& Company, LLP, a public accounting and consulting firm, where he provided audit
compliance and consulting services for that firm's publicly held clients. During
March 2002 through  November  2002,  Mr. King served as the Controller and Chief
Financial  Officer for Peregrine  Industries,  Inc. (a  manufacturer of swimming
pool  heaters)  where he managed  accounting,  prepared  SEC  filings  and other
financial reporting. From November 2000 until March 2002, Mr. King served as the
Controller  and Chief  Financial  Officer  for  NetGain  Development,  Inc.  (an
internet  development  company)  where he managed  accounting  and  prepared SEC
filings. He received a B.S. in Business  Administration from St. Thomas Acquinas
College  and  is  a  member  of  the  American  Institute  of  Certified  Public
Accountants and the Florida Institute of Certified Public Accountants.

     MATTHEW  J.  COHEN.  Mr.  Cohen is the Chief  Financial  Officer  and Chief
Operating  Officer of Cavit.  Mr.  Cohen has been an  officer  and  director  of
PrimEdge (PEDI.PK) since September 20, 2006. Since January 17, 2005, he also has
been the Chief  Executive  Officer and Chief  Financial  Officer of Genio Group,

                                       24
<PAGE>
Inc.  (GNOI.OB)  and since August 1, 2004,  a member of its Board of  Directors.
Prior to these engagements,  Mr. Cohen has served as the Chief Financial Officer
for several companies across a variety of industries. From May 2004 to May 2005,
he was the Chief Financial  Officer of Sea Aerosupport,  Inc. From February 2003
to February  2004, Mr. Cohen was Chief  Financial  Officer of Mark Fore & Strike
Holdings,  Inc., an apparel  retailer.  From July 2002 until  February  2003, he
served as Chief Financial  Officer for Life Imaging  Corporation,  a provider of
diagnostic  services.  From  September 1999 until June 2002, Mr. Cohen was Chief
Financial  Officer for Interactive  Technologies.com,  (INTR.PK),  a benefit and
services  company,  where  he  continues  today  as a  member  of its  Board  of
Directors. Mr. Cohen specializes in the development of financial and operational
infrastructure  and corporate recovery work. Some of his  responsibilities  have
included the implementation and interfacing of information systems indigenous to
the service business. In addition, he also manages all treasury functions, human
resource management,  payroll and management  reporting.  Mr. Cohen has a B.B.A.
degree in Accounting from New Paltz State University, New York.

     RAYMOND S. BAZLEY. Mr. Bazley is a self-employed,  successful  businessman.
Mr. Bazley has owned and operated  Bazley's LLC, in its Feed,  Tack, Pet and Vet
Stores from 1989 to 2005. Mr. Bazley is also the Chief Executive,  Financial and
Operating  Officer of RayMels LLC, a bar and restaurant.  Mr. Bazley also serves
as a consultant to Hard to Treat. Mr. Bazley is also real estate investor.

COMMITTEES OF THE BOARD OF DIRECTORS

     We currently have an audit committee and a compensation committee.

     AUDIT COMMITTEE. The Audit Committee of the Board currently consists of
two  members  of our board of  directors;  Messrs.  Bazley  and King.  The audit
committee  selects,  on behalf of our board of directors,  an independent public
accounting  firm to be engaged to audit our financial  statements,  discuss with
the  independent  auditors  their  independence,  review and discuss the audited
financial  statements with the independent auditors and management and recommend
to our board of directors  whether the audited  financials should be included in
our annual reports to be filed with the SEC.

     COMPENSATION  COMMITTEE.  The Compensation Committee consists of the entire
board of directors.  The Compensation Committee will review and must approve the
annual salary and other  compensation of our executive officers and compensation
to our directors.

COMPENSATION OF DIRECTORS

     During 2007, we issued 263,395 restricted shares of our common stock to the
directors who served on our board of directors.

     During  2006,  each of our five  directors  was issued  100,000  restricted
shares of our common  stock in  consideration  of their  service on our board of
directors.  These shares were issued for  services as  Directors  from April 12,
2006, to December 31, 2006.

     There are no arrangements or understandings between any of the directors or
executive  officers,  or any other person or person  pursuant to which they were
selected as directors and/or officers.

                                       25
<PAGE>
DIRECTORSHIPS

     No  Director  of the  Company  or  person  nominated  or chosen to become a
Director holds any other  directorship in any company with a class of securities
registered pursuant to Section 12 of the 1934 Act or subject to the requirements
of Section  15(d) of such Act or any other  company  registered as an investment
company under the Investment Company Act of 1940.

SIGNIFICANT EMPLOYEES

     No other significant employees exist.

FAMILY RELATIONSHIPS

     The only family  relationship  between or among the Company's  officers and
directors is between Susan King and Colm J. King.  Susan King,  the wife of Colm
J. King, our President and Chief Executive  Officer,  entered into an employment
agreement   with  Cavit   pursuant  to  which  she  serves  as  Accountant   and
Administrator. Ms. King's employment agreement commenced on November 1, 2007 and
runs for one year.  Ms.  King's  salary is $60,000  per year.  Ms.  King did not
receive a cash salary  during  2007,  as two months of her salary was accrued in
2007 and payable in 2008.

INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS

     During the past five  years,  no  present  director,  executive  officer or
person nominated to become a director or an executive officer of the Company:

     (1)  had a  petition  under  the  federal  bankruptcy  laws  or  any  state
          insolvency  law filed by or against,  or a receiver,  fiscal  agent or
          similar  officer  appointed by a court for the business or property of
          such person,  or any  partnership in which he was a general partner at
          or within two years before the time of such filing, or any corporation
          or business  association  of which he was an  executive  officer at or
          within two years before the time of such filing;

     (2)  was  convicted  in a  criminal  proceeding  or  subject  to a  pending
          criminal  proceeding  (excluding  traffic  violations  and other minor
          offenses);

     (3)  was  subject  to any  order,  judgment  or  decree,  not  subsequently
          reversed,   suspended   or   vacated,   of  any  court  of   competent
          jurisdiction,   permanently  or  temporarily  enjoining  him  from  or
          otherwise limiting his involvement in any of the following activities:

          (i)  Acting  as a futures  commission  merchant,  introducing  broker,
               commodity trading advisor, commodity pool operator, floor broker,
               leverage transaction merchant,  any other person regulated by the
               Commodity Futures Trading Commission,  or an associated person of
               any of the foregoing,  or as an investment adviser,  underwriter,
               broker or  dealer  in  securities,  or as an  affiliated  person,
               director or employee of any investment company, bank, savings and
               loan  association  or  insurance  company,   or  engaging  in  or
               continuing  any  conduct  or  practice  in  connection  with such
               activity;

          (ii) Engaging in any type of business practice; or

                                       26
<PAGE>
          (iii)Engaging in any activity in connection  with the purchase or sale
               of any security or commodity or in connection  with any violation
               of federal or state securities laws or federal  commodities laws;
               or

     (4)  was the  subject of any order,  judgment or decree,  not  subsequently
          reversed,  suspended  or  vacated,  of an federal  or state  authority
          barring,  suspending  or otherwise  limiting for more than 60 days the
          right of such person to engage in any activity  described in paragraph
          (3) (i),  above,  or to be associated with persons engaged in any such
          activity; or

     (5)  was found by a court of competent  jurisdiction  (in a civil  action),
          the  Securities  and  Exchange  Commission  or the  Commodity  Futures
          Trading  Commission to have violated a federal or state  securities or
          commodities  law, and for which the  judgment  has not been  reversed,
          suspended or vacated.

SECTION 16 (a) BENEFICIAL OWNERSHIP COMPLIANCE

     Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
executive  officers,  directors and persons who own more than ten percent of the
Company's Common Stock, to file initial reports of beneficial  ownership on Form
3,  changes  in  beneficial  ownership  on  Form 4 and an  annual  statement  of
beneficial ownership on Form 5, with the SEC. Such executive officers, directors
and greater than ten percent  shareholders  are required by SEC rules to furnish
the Company with copies of all such forms that they have filed.

     Based  on its  review  of the  copies  of such  forms  filed  with  the SEC
electronically,  received  by  the  Company  and  representations  from  certain
reporting  persons,  the  Company  believes  that  during the fiscal  year ended
December 31, 2007,  all the  officers,  directors  and more than 10%  beneficial
owners have  complied with the above  described  filing  requirements,  with the
exception (i)  Christopher  Brown and Cortland Fund, LLC who were  delinquent in
the filing of Forms 4 and 5; Harvey  Judkovitz  who is delinquent in filing of a
Form 4; and Julio De Leon who is delinquent in filing of a Form 4 and Form 5.

CODE OF ETHICS

     On June 28, 2006,  the Company  adopted a Code of Ethics  applicable to its
officers,   including  its  principal  executive  officer,  principal  financial
officer,  principal  accounting  officer  or  controller  and any other  persons
performing  similar  functions.  The  Code  of  Ethics  was  designed  to  deter
wrongdoing  and promote  honest and ethical  conduct,  full,  fair and  accurate
disclosure,  compliance with laws, prompt internal  reporting and accountability
to adherence to the Code of Ethics.  The Code of Ethics is posted on our website
at  http://www.  cavitsciences.com.  The Code of Ethics will be provided free of
charge by the Company to  interested  parties upon request.  Requests  should be
made in writing  and  directed to the Company at the  following  address:  20 NW
181st Street, Miami, Florida 33169

ITEM 11. EXECUTIVE COMPENSATION.

     The following table sets forth the aggregate  compensation paid and accrued
by the Company for services rendered during the periods  indicated.  The Company
had two executive officers during 2006 and 2007.

                                       27
<PAGE>
                           SUMMARY COMPENSATION TABLE

<TABLE>
<CAPTION>
                                                                     Non-Equity
                                                                     Incentive   Nonqualified
 Name and                                                               Plan       Deferred    All other
 Principal                                       Stock     Option     Compen-      Compen-     Compen-
 Position        Year   Salary($)    Bonus($)   Awards($)  Awards($)  sation($)    sation($)   sation($)     Total($)
 --------        ----   ---------    --------   ---------  ---------  ---------    ---------   ---------     --------
<S>             <C>    <C>          <C>         <C>        <C>        <C>         <C>         <C>           <C>
Colm J. King     2007   $192,000        0        $14,500       0          0            0        $12,000      $218,500
President        2006   $120,000        0        $19,000       0          0            0        $ 3,000      $142,000
and CEO

Julio De Leon    2007   $ 30,000        0        $15,000       0          0            0        $12,000      $ 42,000
CFO              2006   $ 15,000        0        $15,000       0          0            0        $ 3,000      $ 33,000
</TABLE>


                                       28
<PAGE>
     During the year ended December 31, 2007, $192,000 in salary was accrued for
Mr.  Colm  King,  of which  $95,557  was paid.  Half of Mr. De Leon's  salary of
$60,000 for the year 2007 was paid in restricted  common stock,  the balance was
accrued.  Mr. De Leon and Mr. King  received  $12,000 worth of common stock each
for service as a Director during 2007.

     Mr. King also received  50,000 shares of restricted  common stock valued at
$.29 in accordance with his contract.

     During the year ended December 31, 2006, $120,000 in salary was accrued for
Mr.  Colm King,  of which  $30,000  was paid.  Mr. De Leon's  salary was paid in
restricted  common  stock.  Mr. De Leon and Mr. King  received  $3,000  worth of
common stock each for service as a Director during 2006.

EMPLOYMENT CONTRACTS

     The Company  entered into an  employment  agreement  with our President and
Chief Executive Officer, Colm J. King, as of May 1, 2006. The agreement covers a
three year term and  provides for his annual cash  compensation  to be $180,000.
The  agreement  provides  for  salary  increases  of 10% on the first and second
anniversaries  of the agreement,  unless Cavit has no pre-tax  consolidated  net
income,  in which case there will be no salary  increase.  Mr. King will also be
entitled  to  an  annual   incentive  bonus  equal  to  5%  of  Cavit's  pre-tax
consolidated  net  income.  Mr.  King will also  participate  in  Cavit's  other
employee benefits, as well. In addition,  Mr. King will receive 50,000 shares of
restricted  common stock at the beginning of each contract year.  This agreement
may be terminated by Cavit with or without cause.

     On November  11,  2007,  the  Company  entered  into a one year  employment
agreement with Susan King to act as Accountant and Administrator, which provides
for an annual  compensation of $60,000.  As of April 10th, 2008 all compensation
has been accrued.

OTHER COMPENSATORY CONTRACTS

     On January 21, 2008, the Company's  Board of Directors  elected  Matthew J.
Cohen to the office of Chief Financial  Officer.  The Company entered into a one
year  agreement on January 21, 2008.  The  compensation  of $60,000 will be paid
monthly.

     As of  January  18th,  2008  Julio De  Leon's  agreement  to act as CFO was
terminated  and as of March 4th 2008,  Mr.  De Leon  resigned  from the Board of
Directors.

     On January 21, 2008, the Company's  Board of Directors  elected  Matthew J.
Cohen to the office of Chief Financial  Officer.  The Company entered into a one
year  agreement on January 21, 2008.  The  compensation  of $60,000 will be paid
monthly.

     On November  11, 2007 the Company  entered into a one year  agreement  with
Miles Benzler to act as Marketing and Operations  Manager.  The  compensation of
$60,000 will be paid monthly.

     On December 1, 2006, the Company's Board of Directors elected Julio De Leon
to the office of Chief Financial  Officer.  Mr. De Leon had been a member of the
Registrant's  Board of Directors  since May 1, 2006. The Company and Mr. De Leon
entered into a one year agreement dated December 1, 2006 (effective  November 1,
2006), pursuant to which Mr. De Leon would devote 30% of his time to perform his
duties as Chief  Financial  Officer of the  Company in  exchange  for $60,000 in
annual compensation.

                                       29
<PAGE>
STOCK OPTIONS

     As a result of various  notes  payable  that were  converted  into  company
stock,  the Company  issued stock options for  2,500,000  shares of common stock
with a three year life  convertible at (1) 80% of the average price for the five
trading  days prior to the date of  exercise or (2) 80% of the price that shares
are sold by the Company on any  private  placement  memorandum  within the three
year period.

OPTION/SAR GRANTS TABLE

     There were no stock  options/SARS  granted under the Company's stock option
plans to executive officers and directors during fiscal 2006 or 2007.

AGGREGATE OPTION/SAR EXERCISES AND FISCAL YEAR-END OPTION/SAR VALUE TABLE

     There were no exercises of stock  options/SAR by executive  officers during
fiscal 2006 or 2007.

LONG-TERM INCENTIVE PLAN AWARDS

     There were no long-term  incentive  plan awards made during  fiscal 2006 or
2007.

COMPENSATION OF DIRECTORS

     During 2007 our  directors  have been issued a total of 263,395  restricted
shares of our common  stock in  consideration  of their  service on our board of
directors.   Any  future  director   compensation  will  be  determined  by  our
compensation committee.

REPRICING OPTIONS

     During the fiscal years ended  December 31, 2007 and 2006,  the Company did
not reprice any stock options.

ITEM 12. SECURITY  OWNERSHIP OF CERTAIN  BENEFICIAL  OWNERS AND  MANAGEMENT AND
         RELATED STOCKHOLDER MATTERS.

     To our  knowledge,  the following  table sets forth,  as of April 10, 2008,
information regarding the ownership of our common stock by:

     *    Persons who own more than 5% of our common stock
     *    each of our directors and each of our executive officers; and
     *    all directors and executive officers as a group.

                                       30
<PAGE>
     The table sets forth our actual share  ownership as of April 10, 2008. Each
person has sole voting and  investment  power with respect to the shares  shown,
except as otherwise noted.

    Name and Address                   Amount and Nature of Beneficial Ownership
   of Beneficial Owner                       Number                 Percent
   -------------------                       ------                 -------

Colm J. King                               2,329,861                12.01%
20 NW 181st Street
Miami, Florida 33169

Raymond Bazley                             1,635,753                 8.43%
20 NW 181st Street
Miami, Florida 33169

Christopher Brown                          2,723,802(1)             14.04%
16902 Harbor Master Cove
Cornelius, North Carolina 28031

Julio De Leon                              1,281,550                 6.61%
510 NW 159th Street
Pembroke Pines, Florida 33028

Vision International Enterprises, S.A.     1,850,000                 9.54%
522 Balboa Plaza
Balboa Avenue, Panama

Isthmus Investments Management S.A.        1,250,000                 6.44%
P.O. Box 1508
World Trade Centre, Panama

Margaret Smyth                             1,622,386                 8.36%
20 NW 181st Street
Miami, Florida 33169

All officers and directors as a group      3,965,614                20.44%
(2 persons)

----------
(1)  Includes 2,354,396 Cavit shares held of record in the name of Cortland Fund
     LLC of which  Dr.  Brown is the sole  beneficial  owner.  Dr.  Brown is the
     record and beneficial owner of 369,406 of Cavit shares.

                                       31
<PAGE>
     There  are  no  arrangements  or  understandings  among  the  entities  and
individuals  referenced above or their respective associates concerning election
of directors or other any other matters which may require shareholder approval.

ADOPTION OF EMPLOYEE COMPENSATION PLANS

     On December 14, 2006,  the Company's  Board of Directors  adopted the Cavit
Sciences,  Inc. 2006 Employee and Consultant Stock Incentive Plan ("2006 Plan").
The 2006 Plan  covered up to  2,000,000  shares of common  stock,  had a 10 year
term, covered employees,  consultants, officers and directors. The 2006 Plan was
administered by the Board of Directors. No options were granted to, or exercised
by, any of the Company's directors, employees or officers under the 2006 Plan. A
total of 367,893 shares were issued under the 2006 Plan to consultants. The 2006
Plan was terminated by the Board of Directors on January 8, 2008.

     On January 8, 2008,  the  Company's  Board of  Directors  adopted the Cavit
Sciences,  Inc. 2008 Employee and Consultant Stock Incentive Plan ("2008 Plan").
The 2008 Plan covers up to 1,000,000 shares of common stock, has a 10 year term,
covers  employees,  consultants,  officers and directors.  The 2008 Plan will be
administered  by the Board of  Directors.  No options  have been  granted to, or
exercised by, any of the Company's  directors,  employees or officers  under the
2008  Plan.  A total of  277,739  shares  were  issued  under  the 2008  Plan to
consultants in February 2008.

REPRICING OPTIONS

     During the fiscal years ended  December 31, 2007 and 2006,  the Company did
not reprice any stock options.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
         INDEPENDENCE.

     Cavit's Audit Committee is comprised  solely of members of Cavit's Board of
Directors, all of whom are officers of Cavit and all of whom are shareholders of
Cavit.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

INDEPENDENT PUBLIC ACCOUNTANTS

     Cavit has engaged  Berkovits and Company,  LLP as Cavit's new accountant to
serve as the  independent  accounting  firm  responsible  for  auditing  Cavit's
financial statements for the fiscal year ended December 31, 2007.

     The  Company's  independent  accountants  during  2007 and the fiscal  year
ending December 31, 2006 was Infante & Company.

     (1) AUDIT  FEES.  During  the fiscal  year ended  December  31,  2007,  the
aggregate fees billed by the Company's  auditors,  for services rendered for the
audit  of our  annual  financial  statements  and the  review  of the  financial
statements  included in our  quarterly  reports on Form 10-QSB and for  services
provided in connection with the statutory and regulatory  filings or engagements
for 2007,  was $17,600.  During the fiscal year ended  December  31,  2006,  the
aggregate fees billed by the Company's  auditors,  for services rendered for the
audit  of our  annual  financial  statements  and the  review  of the  financial
statements  included in our  quarterly  reports on Form 10-QSB and for  services

                                       32
<PAGE>
provided in connection with the statutory and regulatory  filings or engagements
for 2006, was $7,650.

     (2)  AUDIT-RELATED  FEES.  During fiscal years ended  December 31, 2006 and
2007, our auditors did not receive any fees for any audit-related services other
than as set forth in paragraph (1) above.

     (3) TAX FEES. Our auditors did not provide tax compliance,  tax advice,  or
tax planning advice during the fiscal years ended December 31, 2006 and 2007.

     (4) ALL OTHER FEES. None.

     (5) AUDIT COMMITTEE'S PRE-APPROVAL POLICIES AND PROCEDURES.

     Effective May 6, 2003, the Securities and Exchange Commission adopted rules
that require that before  Principal  Accountants are engaged by us to render any
auditing or permitted  non-audit related service,  the engagement be:

     *    approved by our audit committee (which consists of our entire board of
          directors); or
     *    entered  into  pursuant  to   pre-approval   policies  and  procedures
          established  by the board of  directors,  provided  the  policies  and
          procedures  are detailed as to the  particular  service,  the board of
          directors  is  informed  of  each  service,   and  such  policies  and
          procedures  do not  include  delegation  of the  board  of  directors'
          responsibilities to management.

     The  board  of  directors   pre-approves  all  services   provided  by  our
independent  auditors.  All of the above  services  and fees were  reviewed  and
approved  by the  board of  directors  either  before  or after  the  respective
services were rendered.

     The board of directors has  considered the nature and amount of fees billed
by our  Principal  Accountants  and believes  that the provision of services for
activities  unrelated to the audit is compatible with  maintaining our Principal
Accountants independence.

     During the 2006 and 2007 fiscal years,  the Company's  audit committee used
the  following   pre-approval   procedures  related  to  the  selection  of  our
independent  auditors and the services  they provide:  Unanimous  consent of all
directors via a board resolution.

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

     (a) (1) Financial Statements

     Financial  statements  for  Cavit  Sciences,  Inc.  listed  in the Index to
     Financial  Statements and Supplementary  Data on page F-1 are filed as part
     of this Annual Report.

     (a) (2) Financial Statement Schedule

     Financial  Statement Schedule for Cavit Sciences,  Inc. listed in the Index
     to Financial  Statements  and  Supplementary  Data on page F-1 are filed as
     part of this Annual Report.

     (a) (3) See the "Index to Exhibits" set forth below.

                                       33
<PAGE>
                                  EXHIBIT INDEX

Exhibit No.          Description

3(i).1*   Articles of  Incorporation  of Cavit  Sciences,  Inc.  filed April 12,
          2006,  with the  Secretary  of State of  Florida  (Exhibit  3(i).1  to
          Cavit's  Registration  Statement  on Form  SB-2,  effective  with  the
          Commission on October 16, 2006)

3(i).2*   Articles  of  Amendment  to the  Articles  of  Incorporation  of Cavit
          Sciences,  Inc.  filed on June 9, 2006 with the  Secretary of State of
          Florida  (Exhibit  3(i).2 to Cavit's  Registration  Statement  on Form
          SB-2, effective with the Commission on October 16, 2006).

3(ii)*    By-Laws of Cavit Sciences, Inc. (Exhibit 3(ii) to Cavit's Registration
          Statement on Form SB-2,  effective  with the Commission on October 16,
          2006)

4.1*      Common  Stock  Purchase  Agreement  dated as of May 23,  2006,  by and
          between  Cavit  Sciences,  Inc. and Raymond S. Bazley  (Exhibit 4.1 to
          Cavit's  Registration  Statement  on Form  SB-2,  effective  with  the
          Commission on October 16, 2006).

4.2*      Common  Stock  Purchase  Agreement  dated as of May 12,  2006,  by and
          between Cavit Sciences, Inc. and Robert Hennen (Exhibit 4.2 to Cavit's
          Registration  Statement on Form SB-2, effective with the Commission on
          October 16, 2006).

4.3*      Common  Stock  Purchase  Agreement  dated as of May 25,  2006,  by and
          between  Cavit  Sciences,  Inc. and Cortland  Fund LLC (Exhibit 4.3 to
          Cavit's  Registration  Statement  on Form  SB-2,  effective  with  the
          Commission on October 16, 2006).

4.4*      Common Stock  Purchase  Agreement  dated as of June 14,  2006,  by and
          between  Cavit  Sciences,  Inc.  and  Margaret  Smyth  (Exhibit 4.4 to
          Cavit's  Registration  Statement  on Form  SB-2,  effective  with  the
          Commission on October 16, 2006).

4.5*      Asset  Purchase  Agreement  dated as of May 31,  2006,  by and between
          Cavit Sciences,  Inc. and Hard to Treat Diseases, Inc. (Exhibit 4.5 to
          Cavit's  Registration  Statement  on Form  SB-2,  effective  with  the
          Commission on October 16, 2006)

4.6*      Cavit  Sciences,  Inc.  Certificate  of Common  Stock  (Exhibit 4.6 to
          Cavit's  Registration  Statement  on Form  SB-2,  effective  with  the
          Commission on October 16, 2006)

4.7*      Management,  Advisory and Support  Agreement dated as of June 1, 2006,
          by and between Cavit Sciences,  Inc. and Hard to Treat Diseases,  Inc.
          (Exhibit 4.7 to Cavit's Registration Statement on Form SB-2, effective
          with the Commission on October 16, 2006)

4.8*      Assignment  Agreement  between Dr. Leland Shapiro and Cavit  Sciences,
          Inc. dated July 7, 2006 (Exhibit 4.8 to Cavit's Registration Statement
          on Form SB-2, effective with the Commission on October 16, 2006).

                                       34
<PAGE>
4.9+      Cavit  Sciences,  Inc. Class A Warrant to Purchase Common Stock Issued
          on January 11, 2008, to Vision International Enterprises, S.A.

4.10+     Schedule of  Documents  similar to Exhibit 4.9 that have been  omitted
          from this Annual Report on Form 10-K (with an  explanation of material
          details in which such omitted documents differ from Exhibit 4.9).

4.11+     Cavit  Sciences,  Inc. Class A Warrant to Purchase Common Stock Issued
          on January 11, 2008, to Isthmus Investments Management, S.A.

4.12+     Schedule of  Documents  similar to Exhibit 4.11 that have been omitted
          from this Annual Report on Form 10-K (with an  explanation of material
          details in which such omitted documents differ from Exhibit 4.11).

4.13+     Cavit  Sciences,  Inc. Class H Warrant to Purchase Common Stock Issued
          on October 26, 2007, to Cortland Fund, LLC.

4.14+     Schedule of  Documents  similar to Exhibit 4.13 that have been omitted
          from this Annual Report on Form 10-K (with an  explanation of material
          details in which such omitted documents differ from Exhibit 4.13).

10.1*     Employment  Agreement dated May 1, 2006, between Cavit Sciences,  Inc.
          and Colm J. King  (Exhibit 10.1 to Cavit's  Registration  Statement on
          Form SB-2, effective with the Commission on October 16, 2006).

10.2*     Agreement  between  Cavit  Sciences,  Inc.  and  Julio  De Leon  dated
          December 1, 2006 (effective November 1, 2006) (Exhibit 10.1 to Cavit's
          Current  Report on Form 8-K filed with the  Commission on December 18,
          2006).

10.3*     Cavit Sciences, Inc. 2006 Employee and Consultant Stock Incentive Plan
          Adopted  December 14, 2006 (Exhibit 99.2 to Cavit's  Current Report on
          Form 8-K filed with the Commission on December 18, 2006).

10.4+     Cavit Sciences, Inc. 2008 Employee and Consultant Stock Incentive Plan
          Adopted January 8, 2008.

10.5*     Amended Asset  Purchase & Royalty  Agreement  between Cavit  Sciences,
          Inc. and Daycon  Investors  Associates,  Inc.,  Americare  Nutritional
          Division,  dated  December 28, 2007 (Exhibit  10.1 to Cavit's  Current
          Report on Form 8-K filed with the Commission on January 4, 2008).

10.6*     Lease  Agreement  between Cavit  Sciences,  Inc. and Daycon  Investors
          Associates,  Inc.,  dated  December 28, 2007  (Exhibit 10.2 to Cavit's
          Current  Report on Form 8-K filed  with the  Commission  on January 4,
          2008).

10.7*     Agreement to Engage Dr. Joseph P. D'Angelo as Consultant between Cavit
          Sciences,  Inc. and Dr. Joseph P.  D'Angelo,  dated  December 28, 2007
          (Exhibit  10.3 to  Cavit's  Current  Report on Form 8-K filed with the
          Commission on January 4, 2008).

                                       35
<PAGE>
10.8*     Agreement  between  Cavit  Sciences,  Inc.  and  Vision  International
          Enterprises,  S.A.,  dated  November 29, 2007 (Exhibit 10.1 to Cavit's
          Current  Report on Form 8-K filed with the  Commission on November 30,
          2007).

10.9*     Agreement  between  Cavit  Sciences,   Inc.  and  Isthmus  Investments
          Management,  S.A.,  dated  November 29, 2007  (Exhibit 10.2 to Cavit's
          Current  Report on Form 8-K filed with the  Commission on November 30,
          2007).

14*       Code of Ethics (Exhibit 14 to Cavit's  Registration  Statement on Form
          SB-2, effective with the Commission on October 16, 2006).

16.1*     Letter from Infante & Company dated  February 6, 2008 (Exhibit 16.1 to
          Cavit's  Current  Report  on Form 8-K  filed  with the  Commission  on
          February 6, 2008).

21+       Subsidiaries.

31.1+     Certification  of Principal  Executive  Officer  Pursuant to 18 U.S.C.
          Section 1350 and Section 302 of The Sarbanes-Oxley Act of 2002.

31.2+     Certification  of Principal  Financial  Officer  Pursuant to 18 U.S.C.
          Section 1350 and Section 302 of The Sarbanes-Oxley Act of 2002.

32.1+     Certification  of Principal  Executive  Officer  Pursuant to 18 U.S.C.
          Section 1350 and Section 906 of The Sarbanes-Oxley Act of 2002.

32.2+     Certification  of Principal  Financial  Officer  Pursuant to 18 U.S.C.
          Section  1350  and  Section  906 of The  Sarbanes-Oxley  Act of  2002.

----------
* Exhibits incorporated herein by reference. (1) File No. 000-52263.

+ Filed herewith.

                                       36
<PAGE>
                                   SIGNATURES

     In accordance  with Section 13 or 15(d) of the  Securities  Exchange Act of
1934,  the  Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.

                            Cavit Sciences, Inc.


Dated: April 17, 2008            /s/ Colm J. King
                                 -----------------------------------------------
                            By:  Colm J. King
                            Its: President and Chief Executive Officer

     In accordance  with the  Securities  Exchange Act of 1934,  this report has
been signed below by the following  persons on behalf of the  Registrant  and in
the capacities and on the dates indicated.


Dated: April 17, 2008            /s/  Colm J. King
                                 -----------------------------------------------
                            By:  Colm J. King
                            Its: President, Chief Executive Officer and Director
                                 (Principal Executive Officer)


Dated: April 17, 2008            /s/ Matthew J. Cohen
                                 -----------------------------------------------
                            By:  Matthew J. Cohen
                            Its: Chief Financial Officer and Secretary
                                 (Principal Financial Officer and Principal
                                 Accounting Officer)


Dated: April 17, 2008            /s/ Raymond S. Bazley
                                 -----------------------------------------------
                            By:  Raymond S. Bazley
                            Its: Director

                                       37
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A Development Stage Company)

                              Financial Statements

                                                                     Page Number
                                                                     -----------

Reports of Independent Registered Public Accounting Firms               F-2

Balance Sheet as of December 31, 2007                                   F-4

Statements of Operations for the Year ended December 31, 2007,
the period from April 12, 2006 (inception) to December 31,
2006 and the cumulative period from April 12, 2006 (inception)
to December 31, 2007.                                                   F-5

Statement of Changes in Stockholders' Deficit for the period
from April 12, 2006 (inception) to December 31, 2007.                   F-6

Statements of Cash Flows for the Year ended December 31, 2007,
the period from April 12, 2006 (inception) to December 31,
2006 and the cumulative period from April 12, 2006 (inception)
to December 31, 2007.                                                   F-7

Notes to Financial Statements                                           F-8

                                      F-1
<PAGE>
             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We have audited the  accompanying  balance sheet of Cavit  Sciences,  Inc. ("the
Company") (a development  stage company) as of December 31, 2007 and the related
statements of operations,  changes in  stockholders'  deficit and cash flows for
the year then ended.  These financial  statements are the  responsibility of the
Company's  management.  Our  responsibility  is to  express  an opinion on these
financial  statements  based on our  audit.  Our  opinion on the  statements  of
operations,  changes in stockholders' deficit and cash flows for the period from
April 12, 2006 (inception) to December 31, 2007 insofar as it relates to amounts
for the  period  prior  to  January  1,  2007 is based  on the  report  of other
auditors.

We conducted  our audit in accordance  with the standards of the Public  Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements  are free of material  misstatement.  The company is not  required to
have,  nor were we engaged to perform,  an audit of its  internal  control  over
financial reporting.  Our audit included  consideration of internal control over
financial  reporting  as  a  basis  for  designing  audit  procedures  that  are
appropriate  in the  circumstances,  but not for the  purpose of  expressing  an
opinion on the  effectiveness  of the company's  internal control over financial
reporting.  Accordingly,  we express  no such  opinion.  An audit also  includes
examining,  on a test basis,  evidence supporting the amounts and disclosures in
the  financial  statements.  An audit also  includes  assessing  the  accounting
principles  used  and  significant  estimates  made  by  management,  as well as
evaluating the overall  financial  statement  presentation.  We believe that our
audit provides a reasonable basis for our opinion.

In our opinion,  the financial  statements  referred to above present fairly, in
all material  respects,  the financial  position of Cavit  Sciences,  Inc. as of
December 31, 2007,  and the results of its operations and its cash flows for the
year then ended in conformity with accounting  principles  generally accepted in
the United States of America.

The  accompanying  financial  statements  have been  prepared  assuming that the
Company  will  continue  as a  going  concern.  As  discussed  in  Note 1 to the
financial  statements,  the Company's  dependence on outside financing,  lack of
sufficient  working capital,  and recurring losses raise substantial doubt about
the Company's  ability to continue as a going  concern.  Management's  plans are
described in Note 1 to the financial statements. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.



/s/ Berkovits & Company, LLP
------------------------------------
Ft. Lauderdale, Florida
April 16, 2008

                                      F-2
<PAGE>
             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We have  audited  the  accompanying  balance  sheet of Cavit  Sciences,  Inc. (a
development stage company) as of December 31, 2006 and the related statements of
operations,  changes in stockholders'  equity and cash flows for the period from
April 12,  2006 (date of  inception)  to  December  31,  2006.  These  financial
statements   are  the   responsibility   of  the   Company's   management.   Our
responsibility  is to express an opinion on these financial  statements based on
our audit.

We conducted  our audit in accordance  with the standards of the Public  Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement.  An audit includes examining, on a
test basis,  evidence  supporting  the amounts and  disclosures in the financial
statements.  An audit also includes assessing the accounting principles used and
significant  estimates  made by  management,  as well as evaluating  the overall
financial  statement  presentation.   We  believe  that  our  audit  provides  a
reasonable basis for our opinion.

In our opinion,  the financial  statements  referred to above present fairly, in
all material  respects,  the financial  position of Cavit  Sciences,  Inc. as of
December 31, 2006,  and the results of its operations and its cash flows for the
period  from  April  12,  2006  (date of  inception)  to  December  31,  2006 in
conformity with accounting principles generally accepted in the United States.

The  accompanying  financial  statements  have been  prepared  assuming that the
Company will continue as a going concern.  As more fully  described in Note 1 to
the financial  statements,  the Company has negative working capital of $77,216,
has incurred  losses since inception  totalling  $592,871 and has yet to achieve
profitable operations. The Company is working on various alternatives to improve
the Company's financial resources which are also described in Note 1. Absent the
successful  completion of one of these  alternatives,  the  Company's  operating
results will increasingly  become uncertain.  These conditions raise substantial
doubt about the Company's ability to continue as a going concern;  however,  the
financial  statements  do not include any  adjustments  to reflect the  possible
future effects on the recoverability and classification of assets or the amounts
and  classification  of  liabilities  that may result  from the  outcome of this
uncertainty.


/s/ Infante & Company
-------------------------------
Hollywood, Florida
April 4, 2007

                                      F-3
<PAGE>
                               CAVIT SCIENCES, INC
                          (A DEVELOPMENT STAGE COMPANY)
                                  BALANCE SHEET

                                                                    December 31,
                                                                       2007
                                                                    -----------
                                     ASSETS

Current assets:
  Cash                                                              $    14,915
                                                                    -----------

Total current assets                                                $    14,915
                                                                    ===========

                      LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities:
  Accounts payable                                                  $    10,004
  Accrued taxes payable                                                  48,580
  Accrued expenses                                                       32,852
  Accrued wages payable                                                 106,443
  Note payable                                                          250,000
                                                                    -----------

Total current liabilities                                               447,879
                                                                    -----------
Stockholders' Deficit:
  Preferred stock - $.01 par value; 5,000,000 shares authorized,
   none issued or outstanding                                                --
  Common stock - $.01 par value; 45,000,000 shares authorized,
   16,570,424 shares issued and outstanding                             165,704
  Additional paid-in capital                                            959,268
  Stock to be issued                                                     45,171
  Deficit accumulated during the development stage                   (1,603,107)
                                                                    -----------

Total stockholders' deficit                                            (432,964)
                                                                    -----------

Total liabilities and stockholders' deficit                         $    14,915
                                                                    ===========


   The accompanying notes are an integral part of these financial statements.

                                      F-4
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                            STATEMENTS OF OPERATIONS

<TABLE>
<CAPTION>
                                                                                              Cummulative for
                                                                         Period from          the period from
                                                                       April 12, 2006         April 12, 2006
                                                 Year ended            (inception) to         (inception) to
                                                 December 31,           December 31,           December 31,
                                                     2007                   2006                   2007
                                                 ------------           ------------           ------------
<S>                                              <C>                    <C>                    <C>
Revenues                                         $         --           $         --           $         --
                                                 ------------           ------------           ------------
General and administrative expenses
  Office expenses                                     162,223                270,918                433,141
  Write-off of impaired intangible                    250,000                     --                250,000
  Wages                                               173,535                120,500                294,035
  Purchased research and development expenses              --                 88,462                 88,462
  Professional fees                                   219,291                112,991                332,282
                                                 ------------           ------------           ------------
     Total general and administrative expenses        805,049                592,871              1,397,920
                                                 ------------           ------------           ------------

Loss from operations                                 (805,049)              (592,871)            (1,397,920)
                                                 ------------           ------------           ------------
Other expense
  Interest expense                                      5,187                     --                  5,187
  Financing costs                                     200,000                     --                200,000
                                                 ------------           ------------           ------------
     Total other expense                              205,187                    --                 205,187
                                                 ------------           ------------           ------------

Net loss                                         $ (1,010,236)          $   (592,871)          $ (1,603,107)
                                                 ============           ============           ============

Basic and diluted loss per share                 $      (0.07)          $      (0.07)
                                                 ============           ============
Weighted average shares
 used in per share calculation                     13,953,892              8,904,984
                                                 ============           ============
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                      F-5
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                  STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT

<TABLE>
<CAPTION>
                                                            Common Stock
                                                        --------------------   Additional    Accumulated
                                                                        Par     Paid-in    Deficit During  Shares to
                                                        Number         Value    Capital      Development   Be Issued      Total
                                                        ------         -----    -------      -----------   ---------      -----
<S>                                                  <C>            <C>        <C>           <C>          <C>            <C>
Balance at Inception - April 12, 2006                        --      $     --   $     --     $        --    $    --   $        --
Issuance of common stock for cash - at $0.08          2,375,000        23,750    166,250              --         --       190,000
Issuance of common stock to Hard to Treat
 Diseases, Inc. for spin-off - at $0.0171 - Note 2    8,475,000        84,750     60,709              --         --       145,459
Issuance of common stock for consulting
 services - at $0.08                                    455,000         4,550     31,850              --         --        36,400
Issuance of common stock for tranfer agent
 services - at $0.08                                    115,800         1,158      8,106              --         --         9,264
Issuance of common stock for legal
 services - at $0.08                                    314,750         3,147     22,033              --         --        25,180
Issuance of common stock to directors for
 fees - at $0.01                                        300,000         3,000         --              --         --         3,000
Issuance of common stock to directors for
 fees - at $0.08                                        387,500         3,875     27,125              --         --        31,000
Issuance of common stock to CEO & CFO for
 services - at $0.01                                     50,000           500         --              --         --           500
Issuance of common stock to CEO & CFO for
 services - at $0.08                                    562,500         5,625     39,375              --         --        45,000
Issuance of common stock to shareholders for
 anti-dilution - at $0.08                               258,807         2,588     18,116              --         --        20,704
Common shares to be issued to attorney for
 legal services - at $0.30                                   --            --         --              --      4,005         4,005
Common shares to be issued to transfer agent
 for services - at $0.30                                     --            --         --              --      5,143         5,143
Net loss                                                     --            --         --        (592,871)        --      (592,871)
                                                    -----------      --------   --------     -----------    -------   -----------
Balance, December 31, 2006                           13,294,357       132,943    373,564        (592,871)     9,148       (77,216)
Issuance of common stock for legal
 services - at $0.229 and $0.30                          69,087           691     15,199              --     (4,005)       11,885
Issuance of common stock to directors
 for fees - at $0.09                                    166,670         1,667     13,333              --         --        15,000
Issuance of common stock for legal
 services - at $0.289                                    37,138           372     10,399              --         --        10,771
Issuance of common stock to CEO & CFO
 for services - at $0.29                                153,449         1,534     42,965              --         --        44,499
Issuance of common stock for legal
 services - at $0.28                                      6,375            64      1,722              --         --         1,786
Issuance of common stock to directors
 for fees - at $0.349                                    42,860           429     14,571              --         --        15,000
Issuance of common stock to shareholders for
 anti-dilution - at $0.467                              109,430         1,094     49,244              --         --        50,338
Common shares to be issued to transfer agent
 for services - at $0.30                                 17,144           171      4,972              --     (5,143)           --
Issuance of common stock for tranfer agent
 services - at $0.28                                      4,263            43      1,150              --         --         1,193
Issuance of common stock for legal
 services - at $0.46                                      1,630            16        732              --         --           748
Issuance of common stock for legal
 services - at $0.55                                     11,236           112      6,068              --         --         6,180
Issuance of common stock to directors for
 fees - at $0.40                                         37,500           375     14,625              --         --        15,000
Common stock issued for debt conversions              2,564,839        25,648    179,539              --         --       205,187
Issuance of common stock for anti-dilution -
 at $0.65                                                 8,100            81      5,184              --         --         5,265
Issuance of common stock to directors for
 fees - at $0.55                                         16,365           164      8,838              --         --         9,002
Issuance of common stock for legal
 services - at $0.60                                     14,525           146      8,570              --         --         8,716
Issuance of common stock for legal
 services - at $0.56                                     13,152           131      7,234              --         --         7,365
Issuance of common stock for tranfer agent
 services - at $0.60                                      2,304            23      1,359              --         --         1,382
Value of beneficial conversion feature and
 options in debt issued                                      --            --    200,000              --         --       200,000
Common shares to be issued to tranfer agent
 for services - at $0.60                                     --            --         --              --     15,716        15,716
Common shares to be issued  for legal
 services - at $0.60                                         --            --         --              --      4,455         4,455
Common shares to be issued for Investor -
 at $0.20                                                    --            --         --              --     12,500        12,500
Common shares to be issued for Investor -
 at $0.20                                                    --            --         --              --     12,500        12,500
Net loss                                                     --            --         --      (1,010,236)        --    (1,010,236)
                                                    -----------      --------   --------     -----------    -------   -----------
Balance, December 31, 2007                           16,570,424      $165,704   $959,268     $(1,603,107)   $45,171   $  (432,964)
                                                    ===========      ========   ========     ===========    =======   ===========
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                      F-6
<PAGE>
                               CAVIT SCIENCES, INC
                          (A DEVELOPMENT STAGE COMPANY)
                            STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                                                     Cummulative for
                                                                                 Period from         the period from
                                                                               April 12, 2006        April 12, 2006
                                                           Year ended          (inception) to        (inception) to
                                                           December 31,         December 31,          December 31,
                                                              2007                  2006                  2007
                                                           -----------           -----------           -----------
<S>                                                      <C>                    <C>                    <C>
Cash flows from operating activities:
  Net loss                                                 $(1,010,236)          $  (592,871)          $(1,603,107)
  Adjustments to reconcile net loss to net
   cash used in operating activities:
     Stock to be issued for services                                --                 9,148                 9,148
     Stock issued for services                                 168,700               150,344               319,044
     Stock issued pursuant to anti-dilution provisions          55,603                20,704                76,307
     Purchased research and development                             --                88,462                88,462
     Write off of impaired intangible                          250,000                86,997               336,997
     Financing costs                                           200,000                    --               200,000
     Interest expense                                            5,184                    --                 5,184
  Changes in operating assets and liabilities
     Decrease in due from related party                          1,615                 1,238                 2,853
     (Increase) decrease in notes receivable                     5,000                (5,000)                   --
     Increase in accounts payable                               90,036               104,991               195,027
                                                           -----------           -----------           -----------

Net cash used in operating activities                         (234,098)             (135,987)             (370,085)
                                                           -----------           -----------           -----------
Cash flows from investing activities:
  Purchase of intellectual property rights                          --               (20,000)              (20,000)
                                                           -----------           -----------           -----------

Net cash used in investing activities                               --               (20,000)              (20,000)
                                                           -----------           -----------           -----------
Cash flows from financing activities:
  Repayment of note payable                                    (10,000)                   --               (10,000)
  Proceeds from notes payable                                  200,000               190,000               390,000
  Deposit on sale of common stock                               25,000                    --                25,000
                                                           -----------           -----------           -----------

Net cash provided by financing activities                      215,000               190,000               405,000
                                                           -----------           -----------           -----------

Net increase (decrease) in cash                                (19,098)               34,013                14,915

Cash, beginning of period                                       34,013                    --                    --
                                                           -----------           -----------           -----------

Cash, end of period                                        $    14,915           $    34,013           $    14,915
                                                           ===========           ===========           ===========
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                      F-7
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                        NOTES TO THE FINANCIAL STATEMENTS
                                December 31, 2007


Note 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE AND CONTINUANCE OF OPERATIONS

Cavit  Sciences,  Inc.  ("The  Company"  or  "Cavit")  is engaged in  developing
treatments of cancer,  viral infections,  opportunistic  infections,  and immune
enhancers.  The Company's strategy is to develop and commercialize  intellectual
property rights for acquisition by a drug company. Cavit is also a manufacturer,
marketer  and  distributor  of  supplements  lines that have been  designed  and
formulated   to  enhance  and  improve  the   prostate,   maintain  and  support
cardiovascular system and beneficially affect arthritis,  osteoporosis and other
conditions.

Cavit was incorporated on April 12, 2006 under the laws of the State of Florida,
as a wholly owned subsidiary of Hard to Treat Diseases, Inc. ("Parent"), and was
spun-off  as a separate  entity  from the Parent  effective  May 31,  2006.  The
Company's  registration  statement  on  Form  SB-2  became  effective  with  the
Securities and Exchange Commission on October 16, 2006.

At December 31, 2007, the Company has negative working capital of $432,964,  has
incurred  losses since  inception  totalling  $1,603,107  and has yet to achieve
profitable  operations.  The Company's ability to continue as a going concern is
dependent on raising additional capital to fund future operations and ultimately
to attain profitable  operations.  Accordingly,  these factors raise substantial
doubt  as to the  Company's  ability  to  continue  as a  going  concern.  These
financial  statements do not give affect to adjustments  that would be necessary
to the carrying values and  classification of assets and liabilities  should the
Company be unable to continue as a going concern.  Management  plans to continue
raising  funds in order to provide for the  Company's  capital  needs,  however,
there are no assurances that management's plans will be attained.

The financial  statements  of the Company have been prepared in accordance  with
accounting  principles  generally  accepted  in the  United  States of  America.
Because a precise determination of many assets and liabilities is dependent upon
future events, the preparation of financial  statements for a period necessarily
involves  the use of  estimates  which  have been made using  careful  judgment.
Actual results may vary from these estimates.

CASH

For  purposes  of the  statement  of  cash  flows,  the  Company  considers  all
investments  purchased  with a  maturity  of  three  months  or  less to be cash
equivalents.

CONCENTRATION OF CREDIT RISK

The Company has no significant  off-balance-sheet  concentrations of credit risk
such as foreign exchange  contracts,  options contracts or other foreign hedging
arrangements.  The Company  maintains the majority of its cash balances with one
financial institution, in the form of demand deposits.

                                      F-8
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                        NOTES TO THE FINANCIAL STATEMENTS
                                December 31, 2007


Note 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
       (CON'T)

DEVELOPMENT STAGE COMPANY

The Company complies with Financial  Accounting  Standards Board Statement No. 7
and for it's characterization of the Company as a Development Stage Enterprise.

FINANCIAL INSTRUMENTS

The  carrying  value  of  cash,   accounts   payable  and  accrued   liabilities
approximates   their  fair  value  because  of  the  short   maturity  of  these
instruments.  It is  management's  opinion  that the  Company is not  exposed to
significant  interest,  currency or credit risks  arising  from these  financial
instruments.

INCOME TAXES

The  Company  accounts  for  income  taxes  under  the  Statement  of  Financial
Accounting  Standards No. 109,  "Accounting for Income Taxes" ("Statement 109").
Under Statement 109,  deferred tax assets and liabilities are recognized for the
future tax  consequences  attributable  to  differences  between  the  financial
statement  carrying  amounts  of  existing  assets  and  liabilities  and  their
respective  tax bases.  Deferred tax assets and  liabilities  are measured using
enacted  tax rates  expected  to apply to  taxable  income in the years in which
those  temporary  differences  are expected to be  recovered  or settled.  Under
Statement 109, the effect on deferred tax assets and  liabilities of a change in
tax rates is  recognized  in income in the period that  includes  the  enactment
date.

LONG-LIVED ASSETS

The Company  accounts for  long-lived  assets under the  Statements of Financial
Accounting  Standards  Nos.  142 and 144  "Accounting  for  Goodwill  and  Other
Intangible  Assets" and  "Accounting  for  Impairment  or Disposal of Long-Lived
Assets"  ("SFAS  No.  142 and 144").  In  accordance  with SFAS No. 142 and 144,
long-lived assets,  goodwill and certain identifiable intangible assets held and
used by the Company are reviewed for  impairment  whenever  events or changes in
circumstances  indicate  that  the  carrying  amount  of an  asset  may  not  be
recoverable. For purposes of evaluating the recoverability of long-lived assets,
goodwill and  intangible  assets,  the  recoverability  test is performed  using
undiscounted net cash flows related to the long-lived assets.

LOSS PER SHARE

Basic and diluted net loss per common share is computed  based upon the weighted
average common shares outstanding as defined by Financial  Accounting  Standards
No. 128,  "Earnings  Per Share."  During the year ended  December 31,  2007,  of
approximately  118,000  common  shares  were  issued  with a value of $55,603 to
certain  shareholders as a result of anti-dilutive  clauses in their shareholder
agreements with the Company that were triggered due to the issuance of shares to
other shareholders.

                                      F-9
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                        NOTES TO THE FINANCIAL STATEMENTS
                                December 31, 2007


Note 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
       (CON'T)

SHARE-BASED PAYMENT

Effective  January 1, 2006, the Company  adopted SFAS No. 123 (R),  "Share Based
Payment," using the modified  prospective  transition method. SFAS No. 123R is a
revision of SFAS No. 123, Accounting for Stock-Based Compensation, it supersedes
APB Opinion No. 25,  Accounting  for Stock Issued to Employees,  and its related
implementation  guidance.  SFAS No. 123 (R) addresses  all forms of  share-based
payment awards  including  shares issued under  employee  stock purchase  plans,
stock  options,  restricted  stock and stock  appreciation  rights.  During  the
periods ended December 31, 2007 and 2006, the Company issued 104,861 and 375,000
shares,  respectively,  of common  stock  with a value of $26,500  and  $19,500,
respectively, to an employee of the Company. These amounts have been recorded in
General  and   Administrative   expenses  in  the  accompanying   statements  of
operations.

The cost of stock-based compensation awards issued to non-employees for services
are  recorded  at  either  the fair  value of the  services  rendered  or of the
instruments  issued in exchange  for such  services,  whichever  is more readily
determinable,  using the  measurement  date  guidelines  enumerated  in Emerging
Issues Task Force ("EITF") Issue No. 96-18,  "Accounting for Equity  Instruments
that Are Issued to Other Than  Employees for Acquiring,  or in Conjunction  with
Selling,  Goods or  Services."  During the periods  ended  December 31, 2007 and
2006, the Company issued 488,837 and 1,810,550 shares,  respectively,  of common
stock with a value of $142,200 and $130,844,  respectively, to certain providers
of  outside   services.   These  amounts  have  been  recorded  in  General  and
Administrative expenses in the accompanying statements of operations.

RECENT ACCOUNTING PRONOUNCEMENTS

In February  2007,  the FASB issued SFAS No. 159,  "Establishing  the Fair Value
Option for Financial Assets and Liabilities  ("SFAS No. 159").  SFAS No. 159 was
to permit all  entities to choose to elect,  at  specified  election  dates,  to
measure  eligible  financial  instruments at fair value.  An entity shall report
unrealized  gains and losses on items for which the fair  value  option has been
elected in earnings at each  subsequent  reporting  date, and recognize  upfront
costs and fees related to those items in earnings as incurred and not  deferred.
SFAS No. 159 applies to fiscal years  beginning  after  November 15, 2007,  with
early  adoption  permitted  for an  equity  that has also  elected  to apply the
provisions of SFAS No. 157, "Fair Value  Measurements".  An entity is prohibited
from  retrospectively  applying SFAS No. 159,  unless it chooses early adoption.
SFAS No. 159 also  applies to eligible  items  existing at November 15, 2007 (or
early  adoption  date).  The Company is evaluating  the potential  impact of the
adoption of SFAS No. 159 on the Company's consolidated financial statements.

In December 2006, the Financial  Accounting  Standards Board (FASB) issued Staff
Position (FSP) EITF 00-19-2, "Accounting for Registration Payment Arrangements".
This FSP specifies  that the  contingent  obligation to make future  payments or
otherwise  transfer  consideration  under a  registration  payment  arrangement,
whether issued as a separate agreement or included as a provision of a financial
instrument or other agreement,  should be separately  recognized and measured in
accordance  with FASB  Statement  No. 5,  "Accounting  for  Contingencies".  The
guidance is effective for fiscal years beginning  December 15, 2006. The Company
is  evaluating  the  potential  impact of the  adoption  of SFAS No.  159 on the
Company's consolidated financial statements.

                                      F-10
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                        NOTES TO THE FINANCIAL STATEMENTS
                                December 31, 2007


Note 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
       (CON'T)

In September 2006 the Financial  Accounting  Standards Board issued Statement of
Financial  Accounting  Standards No. 157 "Fair Value  Measurements"  (SFAS 157),
which  provides  expanded  guidance  for using fair value to measure  assets and
liabilities.  SFAS 157 establishes a hierarchy for data used to value assets and
liabilities,  and requires  additional  disclosures  about the extent to which a
company  measures assets and liabilities at fair value,  the information used to
measure  fair  value,  and the effect of fair value  measurements  on  earnings.
Implementation  of SFAS 157 is  required  on  December  1, 2007.  The Company is
evaluating the potential impact of the adoption of SFAS No. 157 on the Company's
consolidated financial statements.

In  July  2006,   the   Financial   Accounting   Standards   Board  issued  FASB
Interpretation   No.  48  "Accounting  for   Uncertainty  in  Income   Taxes--an
Interpretation  of FASB Statement 109" (FIN 48), which  clarifies the accounting
for  uncertainty in tax positions taken or expected to be taken in a tax return,
including  issues relating to financial  statement  recognition and measurement.
FIN 48 provides  that the tax effects  from an  uncertain  tax  position  can be
recognized   in   the   financial   statements   only   if   the   position   is
"more-likely-than-not"  of being sustained if the position were to be challenged
by a taxing authority. The assessment of the tax position is based solely on the
technical merits of the position,  without regard to the likelihood that the tax
position  may  be   challenged.   If  an  uncertain   tax  position   meets  the
"more-likely-than-not"  threshold,  the largest  amount of tax  benefit  that is
greater than 50 percent likely of being recognized upon ultimate settlement with
the taxing  authority,  is recorded.  The provisions of FIN 48 are effective for
fiscal years beginning  after December 15, 2006,  with the cumulative  effect of
the change in accounting principle recorded as an adjustment to opening retained
earnings.

Note 2 RELATED PARTIES

During the period ended  December 31, 2007,  the Company  issued  176,854 common
shares with a value of $70,200 to providers of outside services;  263,395 common
shares with a value of $54,000 to  directors  of the Company for their  director
fees;  and 153,449  common  shares with a value of $44,500 to the CEO and CFO of
the Company for their services.

On May 31, 2006, the Company  entered into an Asset Purchase  Agreement with its
former Parent to acquire  intellectual  property rights relating to three patent
applications.  In exchange for the  intellectual  property  rights,  the Company
issued  8,475,000  shares of common  stock to Parent at $0.017  per  share.  The
Company recorded this transaction on its books at Parent's historical cost value
of $145,459 which was comprised of; $56,997, which is the capitalized portion of
the intellectual  property  relating to legal costs, and $88,462 of research and
development expenses.

On June 1, 2006 the  Company  entered  into a  management  advisory  and support
agreement  for a twelve  month  period  with its  former  Parent,  Hard to Treat
Diseases,  Inc.  for $1,000 per month which  includes  the use of office  space.
During the period from April 12, 2006 to December 31, 2006, the Parent collected
funds on behalf of the Company  and repaid  certain  expenses  on the  Company's
behalf. Per the agreement,  the Company paid $7,000 in management  advisory fees
to Hard to Treat  Diseases,  Inc. for the period from April 12, 2006 to December
31, 2006.

                                      F-11
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                        NOTES TO THE FINANCIAL STATEMENTS
                                December 31, 2007


Note 2 RELATED PARTIES (CON'T)

During the period ended December 31, 2006, the Company issued  2,375,000  shares
for cash  totalling  $190,000.  An additional  885,550 common shares were issued
with a value of $70,844 to providers of outside services to the Company; 687,500
common  shares were issued with a value of $34,000 to  directors  of the Company
for their  director  fees; and 612,500 common shares were issued with a value of
$45,500 to the CEO and CFO of the Company for their services.

Under the "2006 Employee and Consultant  Stock Incentive Plan", the directors of
the Company shall be compensated  $3,000 per quarter and the board approved this
payment in December  2006 via the issuance of 37,500  common shares with a value
of $.08 per share.  The CEO and CFO were each  eligible  for year end bonuses of
$15,000  annually and those  bonuses were paid in December 2006 via the issuance
of 187,500 common shares to both the CEO and CFO with a value of $.08 per share.

Note 3 INCOME TAXES

As of December 31, 2007, the Company had a net operating loss  carryforward  for
income tax reporting  purposes of  approximately  $1,600,000  that may be offset
against future  taxable income through 2026.  Current tax laws limits the amount
of loss  available to be offset against future taxable income when a substantial
change in ownership  occurs.  Therefore,  the amount  available to offset future
taxable income may be limited. No tax benefit has been reported in the financial
statements,  because the Company  believes  there is a 50% or greater chance the
carryforwards will expire unused. Accordingly, the potential tax benefits of the
loss carryforwards are offset by a valuation allowance of the same amount.

                                                           2007
                                                       -----------
             Deferred tax assets:
             Net operating loss carryforwards          $ 1,600,000
                                                       -----------
             Gross deferred tax assets                     544,000
             Less:  valuation allowance                   (544,000)
                                                       -----------
             Net deferred tax asset                    $        --
                                                       ===========

Note 4 STOCKHOLDERS' DEFICIT

The Company is authorized to issue 5,000,000  shares of preferred stock $.01 par
value and  45,000,000  shares  of  common  stock  $.01 par  value.  The Board of
Directors may make the provisions of the preferred  stock prior to issuance.  As
of December 31, 2007, no shares of preferred stock have been issued.  During the
period from inception  through December 31, 2007, the Company issued  16,570,424
shares of common  stock to pay for  services,  for cash,  and to acquire  patent
application rights.

During the twelve months ended  December 31, 2007 the Company  issued  3,276,067
shares of common stock at prices ranging from $.08 to $.65 for various  matters.
Of  the  total  shares,  2,564,839  shares  were  issued  as a  result  of  debt
conversion,  593,698 shares were issued for director fees, legal fees,  transfer
agent fees, compensation  and  consulting  fees and  117,530  shares were issued
pursuant to anti- dilution clauses to stockholders.


                                      F-12
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                        NOTES TO THE FINANCIAL STATEMENTS
                                December 31, 2007


Note 4 STOCKHOLDERS' DEFICIT (CON'T)

During the twelve months ended December 31, 2006 the Company  issued  13,294,357
shares of common stock at prices ranging from $.01 to $.30 for various services.
Of the total  shares,  8,475,000  shares  were  issued  for the  acquisition  of
intellectual  property,  2,185,550  shares were issued for director fees,  legal
fees,  transfer agent fees and  consulting  fees,  2,375,000  shares were issued
relating  to stock  sales and  258,807  shares  were  issued  pursuant  to anti-
dilution clauses for previous shares issued.

During the twelve months ended  December 31, 2007 the Company  issued options to
convertible  debt  holders and  warrants to  investors  that agreed to terminate
their  anti-dilution  rights that arose from various stock purchase  agreements.
The options and warrants  shall expire at various  times up to sixty months from
the issue date. Set forth below is the activity during 2007:

                                       Options
                                   at an exercise
                                    price of 80%
                                   of the average
                                   price for the        Warrants
                                  five days prior    at an exercise
                                    to exercise       price of .55       Total
                                    -----------       ------------       -----
Outstanding at December 31, 2006
  Issued                              2,500,000          313,334       2,813,334
  Expired or cancelled                       --               --              --
  Exercised                                  --               --              --
                                      ---------          -------       ---------
Outstanding at December 31, 2007      2,500,000          313,334       2,813,334
                                      =========          =======       =========

Note 5 COMMITMENTS AND CONTINGENCIES

The Company has executed a three year  employment  agreement  with its President
and CEO. The agreement began on May 1, 2006 and calls for annual compensation of
$180,000.  The agreement also allows for annual  increases of 10% from the prior
year's base salary,  50,000 shares of restricted  common stock every six months,
and the other benefits standard to an executive employee.

Note 6 INTANGIBLE ASSET

On  December  28,  2007,  the Company  acquired  formulas,  tests and  packaging
intellectual  property  related to a supplement  line from the Daycon  Investors
Associates,  Inc., Americare Nutritional Division (Daycon). The company issued a
note in the amount of $250,000 as payment for the intellectual property.

Under SFAS 144 "Accounting for the Impairment or Disposal of Long-Lived Assets",
the Company conducted an impairment test of the above mentioned supplement line.
SFAS 144  states  that if the  carrying  amount  of an  asset or asset  group is
evaluated  and  found not to be  recoverable,  then an  impairment  loss must be
recognized. The impairment loss is measured as the excess of the carrying amount
over the asset's fair value. Fair value is determined using quoted market prices
in active markets,  when  available.  If market prices in active markets are not
readily determinable, the Company's  estimated fair value is  based on the  best
information  available  such as  market  prices  for  similar  assets  or  using
valuation  techniques such as the expected present value of future cash flows as
set forth in ASB Concepts Statement 7.

The Company ultimately concluded that the amount assigned to this asset would be
expensed as impaired since it is a unique intellectual property for which a fair
market value is not easily  determinable  and for which a valid  calculation  of
expected  present  value of future cash flows cannot be made.  See  write-off of
impaired intangible in the Statements of Operations.

                                      F-13
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                        NOTES TO THE FINANCIAL STATEMENTS
                                December 31, 2007


Note 7 PATENT ACQUISITION

On May 31, 2006,  the Company  acquired  intellectual  property  rights from its
former  Parent,  consisting  of three  patent  applications.  The  Company  paid
$145,459 by issuing 8,475,000 shares of its common stock at a value of $.017 per
share.  The value paid for such  intellectual  property  consisted of $56,997 in
legal fees and $88,462 of purchased research and development costs ("R&D").  The
Company did not pay for the former Parent's  overhead  expenses  related to R&D.
Such costs  amounted to $47,060  for the period from  January 1, 2004 to May 31,
2006 when the Parent  began to expend  resources  to develop  such  intellectual
property rights.

On July 7, 2006,  the Company  entered into an assignment  agreement  whereby it
acquired a portion of the rights to a patent application entitled,  "Methods and
Compositions for Treatment of Viral Infections".

As required by SFAS 142, the Company  conducted an impairment test of its patent
application  rights to measure  their fair  value (as  defined by SFAS 142).  At
December 31, 2006,  the Company  recorded an impairment  charge of $86,997 which
was  primarily  due to the fact that such  patents are not  currently  producing
revenues or cash flows. The book value of the patent application rights does not
reflect the future  potential  of our patents as the patent  rights are still in
the application phase.

Note 8 NON-CASH FINANCING ACTIVITIES

During the year ended  December 31, 2007, the Company  issued  2,564,839  common
shares pursuant to the conversion of $200,000 of convertible notes and $5,187 of
related accrued interest. In addition, in 2007 the Company issued 593,698 common
shares to outside service providers,  directors, officers, and shareholders with
a value of $168,700.

During the year ended  December 31, 2006,  the Company  recognized  the value of
8,475,000  common shares issued to Hard to Treat  Diseases,  Inc with a value of
$145,459;  and  2,185,550  common shares  issued to outside  service  providers,
directors, officers, and shareholders with a value of $171,048.

Note 9 NOTE PAYABLE

The Company issued a $250,000 note relating to the acquisition of its supplement
line on December 28, 2007 from the Daycon Investors Associates,  Inc., Americare
Nutritional Division (See Note 6). A $25,000 payment was made on the note during
January 2008 to reduce the principal balance to $225,000. Additional payments on
the note  will be made by paying  the note  holder  20% of the  gross  amount of
additional  financing  received by the  Company  until the note is paid in full.
This is an unsecured non-interest bearing note.

                                      F-14
<PAGE>
                              CAVIT SCIENCES, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                        NOTES TO THE FINANCIAL STATEMENTS
                                December 31, 2007


Note 10 CONVERTIBLE DEBT

During the year, the Company issued various  convertible notes payable amounting
to $200,000.  These convertible notes matured at various times within six months
from date of  issuance,  had an interest  rate of 7% and  included a  beneficial
conversion feature which allowed the holder to convert the notes to common stock
at a conversion price of $0.08 per share.  Along with these  convertible  notes,
the Company also issued options expiring three years from date of issuance which
allow the holders to purchase up to  2,500,000  shares of common stock at 80% of
the average  price for the five trading days prior to the date of exercise.  The
notes were all converted into stock on December 16, 2007.

Convertible  debt with beneficial  conversion  features,  whereby the conversion
feature  is "in the  money,"  are  accounted  for in  accordance  with  guidance
supplied  by Emerging  Issues  Task Force  ("EITF")  No.  98-5  "Accounting  for
Convertible  Securities  with  Beneficial  Conversion  Features or  Contingently
Adjustable  Conversion  Ratios" and EITF No. 00-27 "Application of Issue 98-5 to
Certain  Convertible  Instruments."  The relative  fair value of the  beneficial
conversion  feature and related  options was recorded as a discount  against the
convertible  notes up to the amount  received upon the issuance of the notes and
has been amortized into operations through the date of conversion.

The amortization  related to the above discounts has been reflected in financing
costs in the  accompanying  statement of operations  for the year ended December
31, 2007.

Note 11 SUBSEQUENT EVENTS

In January  2008,  the Company  received  the balance of proceeds and issued the
stock  pursuant  to a 2007  Common  Stock  Purchase  Agreements  for the sale of
2,500,000 of the  Company's  unregistered  common stock at $.20 per share.  As a
result of the agreements the Company raised $500,000.  In addition,  the Company
issued 3,000,000 warrants for the Company's common stock at stock prices ranging
from $.40 to $3.00 per share  with  varying  expiration  dates  from the date of
issuance not to exceed the commitment amount.

Commencing in January 2008, the Company  entered into a lease in Miami,  Florida
for  approximately  2,300 square feet of space.  The Company is obligated to pay
approximately $5,300 under this lease which expires on December 31, 2008.

                                      F-15